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To Ray, Egon and Peter
"Everything in this book may be wrong" 
From Illusions by Richard Bach
SUMMARY
This study was undertaken to investigate the 
mechanisms by which a variety of effectors - agonists and 
antagonists - interact with the predominant neuronal 
nicotinic acetylcholine receptor (nAChR), the a4£2 subtype. 
The transfected M10 cell line expresses this subtype upon 
induction, and was used extensively here.
The four agonists - acetylcholine, (-)nicotine, 
cytisine and (+)anatoxin - appeared to be mechanistically 
similar in their action at the agonist binding sites of the 
M10 cell line. All had a very narrow concentration range 
over which they could activate the receptor and elicit 
86Rubidium+ influx, usually in the micromolar range. Dose- 
response curves were invariably bell-shaped, suggesting a 
rapid desensitisation at higher agonist concentrations. 
Extended exposure to agonists promoted a large (two to 
three orders of magnitude) increase in the binding 
affinity. (+)Anatoxin was exceptional, having a high 
affinity in functional studies (EC50 = 48nM), and steeper 
dose-response curves. However, affinity for the 
desensitised state was approximately equal to that of the 
other agonists.
The antagonists were assayed for their ability to 
attenuate agonist-induced 86Rubidium+ flux into M10 cells, 
and for their effects on [3H]nicotine binding to Triton X- 
100 extracts of rat brain membranes. Dihydro-S-erythroidine 
behaved as a competitive antagonist,, reducing the apparent 
affinity of the nAChR for the agonist. The data was
consistent with MK-801 acting as an open-channel blocker, 
though this form of antagonism has an unusually small 
allosteric component and thus.only limited effects on high 
affinty agonist binding. Mecamylamine and chlorisondamine 
had profound, and distinctive effects on agonist binding. 
Mecamylamine may stabilise a structurally discrete 
conformation of the receptor, distinct from that resulting 
from agonist-induced desensitisation. Possible modes of 
antagonism are fully discussed within a general framework.
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1 GENERAL INTRODUCTION
Most intercellular signalling molecules do not 
permeate the plasma membrane, but interact with surface 
receptors. Neurotransmitters generally fit into this group, 
acetylcholine (ACh) for instance, acting at two different 
classes of receptor (the nicotinic and muscarinic), each 
containing a number of subtypes. The members of the 
nicotinic acetylcholine receptor (nAChR) family may, in 
structural and pharmacological terms, be broadly divided 
into two groups: "muscle-" (including those from Torpedo
and Electrophorus electric organs) and "neuronal-type" 
receptors. The identification and biochemical 
characterisation of nAChR in neurons has lagged 
considerably behind that in electric organ and muscle; a 
primary aim of this project is to help redress this 
imbalance.
Generically, nAChR may be considered to consist of 
three distinct domains: the region involved in signal
recognition, a cation selective ion channel, and a region 
accessible to intracellular regulatory processes, such as 
phosphorylation. Although each region is spatially 
discrete, events at one may influence the others; the very 
act of signal transduction is based on ACh binding leading 
to an opening of the channel. The receptor conforms to the 
classical definition of an allosteric protein (Monod et 
al. , 1963) . The project aims to examine possible allosteric 
interactions in neuronal receptors, allowing comparison 
with the more extensively studied muscle types, where
1
applicable, and speculation as to the effect such 
mechanisms have on receptor function.
1.1 nAChR STRUCTURE
1.1.1 The receptor macromolecule
Early structural evidence from Torpedo. based on x- 
ray diffraction (Ross et aJL., 1977), immunoelectron 
microscopy (Klymkowsky et al., 1979) and neutron scattering 
(Wise et al., 1981), suggested a protein 110-12oA in 
length, enclosing a central pore at least 6.5A in diameter 
(Dwyer et al., 1980). The bulk of the protein was shown to 
be in the extracellular domain (extending 50-60A from the 
membrane, compared with IO-20A on the cytoplasmic side; see 
Fig 1.1A), with regions of regular secondary structure, 
probably a-helix (though see section 1.1.3), perpendicular 
to the membrane. These dimensions relate to the quaternary 
structure of an oligomeric molecule; each receptor, in 
Torpedo. actually consists of 5 subunits around a pseudo 
five-fold axis (Brisson & Unwin, 1985) . The subunits are 
not identical, but homologous proteins: a. (of which there 
are two in each receptor), £, r and 5 (Raftery et. al. . 
1980) . They are believed to be arranged such that the £ 
separates the two a. subunits, with the r and 6 next to each 
other (Kubalak et aJL., 1987, see Fig. l.lBi). This has 
recently been disputed however, because such an arrangement 
gives rise to a non-symmetrical positioning of the agonist 
binding sites (Pedersen & Cohen, 1990; see Fig. l.IBii). 
Reports indicate that a pentameric arrangement, including
2
two agonist binding sites, is maintained in neuronal nAChR 
(Anand et al., 1991 and Cooper £t al., 1991). This is not 
immediately obvious, as it appears that only two types of 
subunits, a. and 13, are usually present in neuronal nAChR, 
though multiple subtypes of each have been described (see 
section 1.1.2).
1.1.2 Subunit heterogeneity
The subunit composition of neuronal nAChR contrasts 
markedly with that of the muscle-type receptor, most 
notably in the number of different subunits that appear to 
exist. Thus far, a further ten subunits have been cloned 
from neuronal cDNA libraries (see Table 1.1). Seven of 
these have been identified, by sequence homology and/or 
functional expression, as agonist-binding subunits, 
analogous to the a. of muscle nAChR. These neuronal a 
subunits, a2 to o?8 (that of muscle having been designated, 
retrospectively, cel) , contain residues homologous to those 
labelled by affinity probes in Torpedo nAChR (most notably 
cysteines 192 and 193; see section 1.2.1). These residues 
are not present in the remaining three subunits, which have 
been alternatively designated as 132 to 134 or nono'l to 
nona3, depending upon the species from which they were 
originally cloned (rat or chicken respectively).
The ligand-gated cation channels formed in the 
Xenopus oocyte expression system appear, usually, to 
consist of only one type of agonist-binding subunit, and 
one type of structural subunit. As the interaction of
Table 1.1 Published neuronal nAChR subunits cloned from 
rat and chicken sources.
Subunit Rat Chicken
a.2 Wada et al. (1988) Nef et al. (1988)
o?3 Boulter et al. 
(1986)
a4 Goldman et al. 
(1987)
a5 Boulter et al. 
(1990)
Couturier et al. 
(1990b)
o?6 -
al Couturier et al. 
(1990a), Schoepfer 
et al. (1990)
a8 Schoepfer et al. 
(1990)
S2 (nonal) Deneris'et al. 
(1988)
Nef et al. (1988)
S3 (nona2) Deneris et al. 
(1989)
S4 (nono'3) Duvoison et al. 
(1989)
Couturier et al. 
(1990b)
agonists and antagonists with nAChR is dependent upon both 
the a and non-a subunits present within the oligomer (see 
section 1.2.1), the existence of multiple subunits raised 
the possiblity of multiple pharmacological profiles amongst 
neuronal nAChR. This was demonstrated to some extent by 
Couturier et al. (1990a), who showed that sensitivity to
ACh varied with subunit composition; the subtype displaying 
the highest affinity, g?4S2, is the main interest of this 
project (see section 3.1). Not all the subunits discovered 
appear to form part of a functional nicotinic receptor in 
the Xenopus system however, limiting the theoretical 
diversity. For example, neither o?5 nor S3 form functional 
receptors when combined with any subunit (Boulter et 
al.,1990; Couturier et al., 1990b; Deneris et al., 1989); 
there is other evidence which suggests that a5 can combine 
with two other subunits in a single heterooligomer however 
(Conroy et al. , 1992). Similarly, there are no published
data refering to a6 as being able to form functional 
channels. Conversely, the al subunit is able to form homo- 
oligomeric ion channels; coinjection with £ subunits had no 
effect on the agonist sensitivity of the resultant receptor 
(Couturier et al. , 1990a). However, Schoepfer et al. (1990) 
have suggested that aS may combine with al to form yet 
another receptor subtype.
1.1.3 Subunit topography
Hydropathy profiles of subunit sequence data (Fig. 
1.1C), initially from Torpedo. revealed two main
hydrophilic and four hydrophobic domains (Ml, M2, M3 and 
M4) , the latter of sufficient length to span the plasma 
membrane as a-helices. These data provided the basis of the 
earliest structural model (Noda et al., 1982, 1983; Claudio 
et al.. 1983 and Devillers-Thiery et al., 1983). Consensus 
glycosylation site sequences where located in the first of 
the hydrophilic domains, whilst the intracellular domain 
was situated between the two putative transmembrane helices 
M3 and M4 (Fig. 1.1D). This model was challenged (for 
example by Guy, 1984 and Finer-Moore & Stroud, 1984) . The 
lack of a suitably hydrophilic transmembrane segment to 
line the channel lumen, and the existence of an 
extracellular carboxy-terminal (unlike most other membrane 
protein structures determined at that time) were regarded 
as particularly significant in this context. However, the 
location of a channel-blocker binding site to M2 (see 
section 1.3.1.2), and confirmation of the carboxy-terminal 
orientation (McCrea et al., 1987) added weight to the
initial model, as well as serving to emphasise the 
unconventionality of the the ligand-gated ion channels. 
However, the recent genera'tion of a 9A resolution structure 
of the Torpedo nAChR by Unwin (1993) , has once again raised 
doubt as to the accuracy of this model of subunit 
structure. Only a single a-helix, postulated to be the M2 
segment, was seen in the membrane spanning domain of each 
subunit; no other secondary structures could be resolved in 
this region. Based on these data, Unwin hypothesised that 
the Ml, M3 and M4 segments form S-strands.
1.2 THE "THREE DOMAIN" MODEL
1.2.1 Signal recognition: the agonist binding site
The nAChR has two agonist binding sites (Reynolds & 
Karlin, 1978), both of which must be occupied to open the 
ion channel (Dionne et al., 1978). Binding curves, from 
Torpedo. suggested these sites to be non-identical and 
capable of interacting with positive cooperativity (Oswald 
& Changeux, 1982) . Combination of a with other subunits 
appears to be the basis of these phenomena (Blount & 
Merlie, 1989) . Agonist binding sites are now believed to be 
at the interfaces of a and non-a subunits, both in muscle- 
(Pedresen & Cohen, 1990) and neuronal-type (Luetje & 
Patrick, 1991) nAChR. Affinity labelling with competitive 
antagonists has been used to identify those residues 
involved in agonist binding. Such studies have picked out 
residues in three different regions of the N-terminal 
domain of the a subunit: tyrosines 93 and 190, tryptophan 
149 and cysteines 192 and 193 (Torpedo numbering; see 
Sequence 1.1) . These are conserved in all a, and absent in 
all non-o?, subunits (in most cases: neuronal £ subunits 
contain aromatic residues homologous to tyrosine 93 and 
tryptophan 149) . Similarly, Chiara & Cohen (1992) have 
recently reported the labelling of homologous tryptophan 
residues on the r and 6 subunits. A 13 residue loop, 
anchored by a disulphide bridge between cysteines 128 and 
142, has been suggested to play a role in agonist binding 
(Cockcroft et al., 1990). This structure certainly appears 
to be a key one; deletion of one of the cysteine residues
7
leads to a drastic reduction in nAChR expression and 
activity (Mishina et al. , 1985; Gehle & Sumikawa, 1991). 
However, the presence of the "cys-loop" in non-a subunits, 
and in other members of the ligand gated ion channel super 
family (Betz et, al., 1990), tends to support a more
generalised structural role for this motif.
1.2.2 The ion channel
In nAChR, the central "pore", framed by surrounding 
subunits, can be divided into three regions: two wide
openings, approximately 25A in diameter, on either side of 
the plasma membrane, divided by a much narrower channel, 
less than 10A wide. The boundries between these different 
areas are very sharp and occur at the level of the 
phospholipid head groups (Fig. 1.1D). Although the outer 
regions may have a role in channel function (see section
1.2.2.3), it is the organisation of the transmembrane 
domain, central to nAChR action as a cation selective 
channel, which is addressed here.
1.2.2.1 M2 as the pore-lining segment
Identification of the channel lining segment proved 
one of the decisive factors in the adoption of the current 
model of subunit topology (See section 1.1.2). Support for 
M2 in this role came from several lines of investigation. 
Using DNA expression and single channel recording, it was 
shown that the conductance of a chimeric channel was 
dependent on the M2 segment and adjacent hinge regions
(Imoto et. al., 1986; see also section 1.2.2.2). Binding 
data, using photoaffinity radiolabels based on channel 
blockers such as chlorpromazine (CPZ) and triphenylmethyl 
-phosphonium (TPMP) further implicated M2 as the pore 
lining region, as well as providing information on those 
residues involved in the high affinity site for such 
compounds (see section 1.3.1.2).
1.2.2.2 Barriers to ion permeation
Unwin (1989), noting the preponderance of 
negatively charged residues in the extracellular domain of 
nAChR, elaborated a possible role for this region in ion 
selectivity. The cylindrical shape of the channel in this 
region (see Fig. 1.1C) was envisaged as serving a dual 
function: wide enough so as not to inhibit ion diffusion, 
but sufficiently narrrow that the charged residues exert 
significant electrostatic effects (that is, attracting 
cations and repelling anions) . The main effectors of ion 
selectivity, however, are likely to be located close to, or 
within, the narrow portion of the pore.
By analysis of single channel currents, Imoto et 
al. (1988) identified three clusters of negatively charged 
and glutamine residues as major determinants of the rate of 
ion transport through Torpedo nAChR. These clusters, 
adjacent to the M2 region - hence confirming earlier 
observations, see section 1.2.2.1 - were suggested to form 
three "rings" of charged residues. Using the nomenclature 
given in the review by Changeux (1990), these are: the
INNER- (homologous to a-aspartate 238), OUTER- (a-glutamate 
26^ 2) and INTERMEDIATE (a-glutamate 241) charged rings (see 
Sequence 1.2 for positions relative to M2) . Mutations in 
the intermediate ring exerted the strongest influence on 
single channel conductance, as well as on ion selectivity 
(Konno et al., 19S1), which may imply that the residues of 
this ring come into closest contact with permeating 
cations. The other rings have been suggested to have a role 
in regulating ion access to the channel. It is' worth 
emphasising at this point that these observations fully 
support the still strictly hypothetical a-helical 
configuration assigned to the transmembrane regions, at 
least for M2; the other putative membrane spanning segments 
may be different (see Unwin, 1993).
Dani (1989) showed that one cation binding site 
exists within the pore, through which every ion must pass. 
This narrow region was calculated, by streaming potentials, 
to be approximately 3-6A long (a distance equivalent to one 
or two a-helical turns) . A ring of polar residues within 
the central region of the pore could, by donating a 
hydrogen bond to the carbonyl oxygen on the next helical 
turn, form such a site (Perutz, 1989). It is tempting to 
equate the cation binding site with that for channel 
blockers labelled by CPZ and TPMP (See section 1.3.1.2), 
which is located two helical turns from the intermediate 
charged ring (See Fig. 1.2). Both sites may, after all, be 
envisaged as constrictions within the channel. However, 
changes in conductance elicited by mutations at this site
were negligible (Leonard et al., 1988 and Charnet et al., 
1990) . Recently, Imoto et al. (1991) have shown a ring of 
hydrophilic residues, homologous to a-threonine 244 
(position 2; Sequence 1.2), to have profound effects on 
single channel currents when mutated. It was suggested that 
this HYDROPHILIC ring, and the intermediate charged ring, 
form, the constriction which is the basis of the cation 
binding site. In favour of this hypothesis are: the size of 
this putative site, calculated to be approximately 5‘.4A, 
and the high degree of conservation evident at these 
positions, the hydrophilic ring residues are invariably 
serine or threonine in the muscle and neuronal subunits of 
birds and mammals. Channel blockers, whilst also 
interacting with hydrophilic residues, may simply be 
incapable of penetrating beyond their high affinity site; 
Furois-Corbin & Pullman (1989) calculated the M2 helices to 
tilt approximately 7°, creating, in effect, a narrowing 
channel. Interestingly, White & Cohen (1992) reported that 
the location of channel blocker binding is dictated by the 
degree of access allowed to the antagonist. They showed 
that whilst a channel blocker (3-(trifluoromethyl)-3-(m- 
[12SI] iodophenyl) diazarine) labelled Torpedo nAChR in both 
the absence and presence of an agonist, only in the latter 
case was antagonist bound at the high-affinity channel 
blocker site.
The possible application of this four-ring 
"structure" to the neuronal a4£2 subtype using sequence 
alignments, is illustrated in Fig. 1.3.
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1.2.3 Intracellular modulation - phosphorylation
Protein phosphorylation is a major regulatory 
mechanism, likely to have a role in the control of almost 
all cellular pathways. The effectors of this system are the 
protein kinases and phosphatases. The former catalyse the 
covalent transfer of the r-phosphate of adenosine 
trisphosphate (ATP) to specific - serine, threonine or 
tyrosine - residues of the target protein,- the latter, its 
removal. The addition of such a charged group would be 
envisaged to cause changes in protein structure, thereby 
regulating function.
1.2.3.1 Subunit specificities
It has long been established that isolated post 
synaptic membranes from Torpedo have protein kinase 
activity (Gordon et al., 1977a), and that this was able to 
act on nAChR (Gordon et. al., 1977b) , Later studies were
able to associate this activity with three endogenous 
kinases: cAMP dependent kinase, phosphorylating r and 6
subunits (Huganir & Greengard, 1983) , protein kinase C, 
acting on al and 8 subunits (Huganir et al., 1983), and a 
tyrosine specific kinase, targetting £, r and 6 subunits 
(Huganir et al., 1984) .
Avian and mammalian muscle-type receptors were 
shown to be similarly phosphorylated by means of 
radiolabelling, with phosphorus-32, both primary cultures 
and clonal cell lines. Under basal conditions, chick 
myotubes were found to have labelled r and 6 subunits (Ross
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et al. . 1987), whilst those from rat (Miles et al., 1987) 
and and' BC3H1 myocytes (Smith et al. , 1987) had
phosphorylated £1 and 6 subunits. Additionally, forskolin 
(an activator of adenylate cyclase) and cAMP analogues 
induced labelling of the al subunit in BC3H1 cells. 
Recently, again using similar techniques, neuronal nAChR 
have been.shown to be phosphoproteins. Using chick cilliary 
ganglia, Vijayaraghavan et al. (1990) reported a3 to be 
phosphorylated in response to cAMP analogues. Whiting 
(unpublished results) has demonstrated a4 to be basally 
phosphorylated in the M10 cell line, whilst forskolin 
treatment promotes the phosphorylation of £2 subunits.
1.2.3.2 Functional effects of phosphorylation
It was postulated that, if nAChR could be 
phosphorylated (see section 1.2.3.1), then this must 
modulate channel function (Saitoh & Changeux, 1981). 
However, as purified receptor preparations were active in 
the absence of ATP (Tank et al. , 1983), phosphorylation
could not be a prerequisite of normal activity. Huganir et 
al. (1986) showed that, although no difference was apparent 
in initial conductance rates, or indeed sensitvity to 
agonist, the rate of desensitization of purified and 
reconstituted Torpedo nAChR was greater for phosphorylated 
receptors. Investigations using muscle-type receptors in 
less artificial systems confirmed this, as well as the 
involvement of the endogenous kinases. Application of 
forskolin to rat soleus muscle end plates (Middleton et
13
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al., 1986) caused a rapid increase in the rate of 
desensitisation; analogues which could not activate 
adenylate cyclase had no effect (Albuquerque et al.( 1986) . 
Activation of protein kinase C in chick myotubes had 
previously been shown to reduce the sensitvity of nAChR to 
agonist (Eusebi et al., 1985) .
The situation for neuronal nAChR appears less 
clear. Acute treatment of PC12 cells with forskolin had no 
effect on receptor properties (McGee & Liepe, 1984) . 
Although a reduction in response was observed in rat 
sympathetic ganglia (Akagi & Kudo, 1985), this may have 
been due to a direct inhibition by forskolin (McHugh & 
McGee, 1985) . Conversely, in chick ciliary ganglia, cAMP 
analogues increased the overall ACh response, whilst only 
having a small effect on desensitisation rate (Margiotta et 
al., 1987). This was achieved by an increase in the number 
of functional channels, though apparently not by a 
stimulation of de novo synthesis.
As well as these direct effects, it has been 
suggested that phosphorylation may have a role in nAChR 
biosynthesis and agregation at the synapse. In chick muscle 
cultures, for example, the phosphorylation status of the 6 
subunit changes as it is incorporated into the complete 
oligomer (Ross et al.,1987). Such alterations are likely in 
other subunits.
1.3 MODELS OF nAChR FUNCTION
1.3.1 The 1 four-state" model
As with many other features of nAChR, the kinetic 
model of its interaction with agonists is derived from 
extensive analysis of data from the muscle-type receptor. 
As this has been reviewed in great detail elsewhere (Ochoa 
et al., 1989 and Changeux, 1990 for example), only the key 
features of the model, and the some of the experimental 
observations behind them, are dealt with here.
Prolonged exposure to agonist was found to lead to 
a time-dependent reversible decrease of the response called 
"desensitisation" (Katz & Thesleff, 1957) . This phenomenon 
was found to be kinetically complex, consisting of two 
distinct processes: a fast one, which led to a thousand­
fold decrease in ion transport, and a slow one, in which 
ion movement through the channel was undetectable (Walker 
et al., 1982) .
Early attempts to correlate the opening of the ion 
channel with agonist binding met with a puzzling paradox. 
The dissociation constant (Kd) of ACh was found to be in 
the region of lOnM (Weber & Changeux, 1974) , some 4 to 5 
orders of magnitude below that for the permeability 
response. Studies using either [3H]ACh (Boyd & Cohen, 1980), 
or a flourescent agonist, Dansyl-Cg-Choline (Hiedmann & 
Changeux, 1979), showed that under resting conditions 
around one fifth of the receptor population exists in a 
state of high affinity for agonists, the rest in one of low 
affinty. Two major conformational transitions were resolved
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during extended exposure to agonists, the slower of which 
was characterised by high affinty agonist binding and 
formed the majority at equilibrium.
Comparisons, performed in parallel, of the kinetics 
of agonist binding and receptor desensitisation revealed 
that the slow transition state of the former coincided 
exactly with the slow desensitisation phase of the latter 
(Neubig et at.', 1982) . The faster transition, which gave
rise to an intermediate binding state with an apparent 
affinity of approximately 1/xM (Heidemann & Changeux, 1979) , 
fitted with the fast desensitisation.
The simplest minimal model compatible with these 
observations is an adapted version of the concerted model 
for allosteric transitions (Monod et al. , 1965) and that
proposed by Katz & Thesleff (1957) to account for 
desensitisation (see Fig 1.4A). It has four discrete, 
interconvertible states, namely: resting (R), active (A), 
intermediate (I) and desensitised (D). The channel is open 
in the A state, whilst the I and D states are the products 
of rapid and slow desensitisation, respectively. The same 
agonist binding sites are presumed to be involved in all 
four states, though their affinity increases from R to D, 
via A and I .
1.3.2 The model and neuronal nAChR
Depending upon their subunit composition, neuronal 
nAChR vary in their basic physiological properties such as 
agonist sensitivity (see section 1.1.2). Does this extend
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to other aspects of receptor function, such as 
desensitisation? Both a (Gross £t al., 1991) and £ 
(Cachelin & Jaggi/ 1991) subunits appear to have a role in 
defining the desensitisation profile of a given subtype. 
The molecular mechanisms underlying desensitisation of the 
neuronal subtypes are assumed, on the basis of structural 
homologies, to be similar to those in the muscle nAChR (see 
section 1.3.1). The a4£2 subtype, in these terms is very 
similar to the muscle receptor; its affinity for ACh when 
in the R state is micromolar (Bertrand et al. , 1990; see 
section 3.1.3.1), whilst, a biphasic desensitisation is 
believed to give rise to a D state which binds agonist with 
high (nanomolar) affinity (Whiting & Lindstrom, 1986; see 
section 3.1.1). Other subtypes appear less like the muscle- 
type nAChR in this respect.
In the rat phoechromocytoma PC12 cell line, the 
affinity of the receptor for ACh increases only moderately 
during an extended period of exposure to the agonist (Kemp 
Sc Morley, 1986) . PC12 cells are unlikely to express only 
one receptor subtype however. The a3 subunit is certainly 
present, this cell line .having been the source of the 
original clone (Boulter et al., 1986). Analysis of total 
PC12 RNA by Rogers et al. (1992) has shown oi5, £2, £3 and 
£4 to also be present. A similar range of subunits has been 
reported to present in sympathetic ganglia (Listeraud et 
al. . 1991), though this is unsurprising when the adrenal
origin of the PC12 cell is considered (Greene & Tischler, 
1976) . Sympathetic ganglia also have high levels of al
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subunit gene expression, whilst PC12 cells have been shown 
to bind a-BgTX (Patrick & Stallcup, 1977) . The relative 
levels of expression suggest that the dominant receptor 
subtype contains a3 and £4 subunits; a5 may also be 
coexpressed, as appears to be the case in ciliary ganglia 
(Vernallis et. al. , 1993) . Interestingly, a combination of 
a3 and £4 subunits in Xenopus oocytes has been shown 
recently to desensitise only slightly, with the rapid 
initial phase reducing peak response by only 10 to 20% at 
high agonist concentrations (Cachelin & Jaggi, 1991). It 
seems likely that the small increase in agonist affinity 
and this limited desensitisation are linked, and that the 
underlying mechanisms at the a3S4 subtype are similar to 
those in muscle nAChR. A comparative lack of 
desensitisation may be inferred from functional dose- 
response data for agonists at PC12 cells. Lukas (1989) 
showed agonist-induced ion flux to fall only slightly at 
concentrations above those which elicited maximal response 
in most instances. An exception was ACh, which produced a 
profound attenuation of ion movement. This effect was 
observed at very high (5 to lOmM) concentrations, probably 
sufficient for ACh to sterically block the ion channel.
The a.1 homo-oligomer also appears to have a
desensitisation profile differing from the muscle-type
nAChR. Desensitisation was found to be both very fast and 
very thorough (Couturier et al., 1990a). Of greater
interest are the recent studies in which the structural 
basis of desensitisation has been probed, using this
receptor as a model. Mutation of a leucine residue in the 
M2 region (position 9; see Sequence 1.2) not only disrupted 
the high affinity channel blocker binding site (see section
1.4.1.2), but additionally decreased the rate of 
desensitisation of the response (Revah et al., 1991). One 
of the mutants (in which the leucine residue was changed to 
a threonine) was found to exhibit a second conductance 
state. This was only seen under conditions in which the 
wild-type receptor would be desensitised, namely: in the 
presense of competitive antagonists, or after extended 
exposure to agonists (Bertrand et al• / 1992). These
observations have given rise to a modification of the four- 
state model. The nAChR is now considered to have multiple, 
structurally discrete desensitised states instead of just 
one as formerly believed (see Fig. 1.4B). In at least one 
of these conformations, the ion channel is occluded by a 
ring of highly conserved, homologous leucine (position 9, 
see sequence 1.2) residues.
1.4 NON-COMPETITIVE INHIBITORS
1.4.1 Sites and modes of action
"Non-competitve inhibitors" (NCI) are taken here to 
be compounds which attenuate ACh-induced ion flux through 
the nAChR channel, but do not, primarily, compete with 
agonists at their recognition site. Often such interactions 
promote and stabilize a desensitised form of the receptor. 
Heterogeneity of NCI action led Heidmann et al. (1983) to 
propose three "sites" at which such molecules may bind to
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nAChR, namely:
(i) a single "high affinity" site, located within the ion 
channel ("perhydrohistrionicotoxin (H12-HTX) sensitive").
(ii) multiple "low affinity" sites, possibly at the 
protein/lipid interface.
(iii) the agonist binding site, classically that at which 
competitive antagonists act.
A combination of NCI structure, concentration and 
relative affinity for each site, it was suggested, 
determined observed effects. To these criteria, the subunit 
composition of nAChR should probably be added (see section
1.4.3). Of these "sites", interaction at the ion channel is 
probably the best characterised (see sections 1.4.1.1 and
1.4.1.2) and may be the most common mode of action, though, 
is by no means universal.
1.4.1.1 Characteristics of the "channel block" mechanism 
The mechanism of NCI channel block was first 
characterised for single .channels in the seminal work of 
Neher & Steinbach (1978), using a local anesthetic, QX-222. 
Classically, channel block is both "agonist-" and "use- 
dependent", that is: the NCI reaches its site by an aqueous 
path accessible only when the channel is open, usually in 
the presence of agonist; the number of channels available 
to subsequent stimulation decreasing in the presence of the 
blocking agent. Recent evidence however, suggests uncharged
NCI may reach the channel via the lipid bilayer (Blanton et, 
al. . 1988), though the exactrmechanism involved is unclear. 
Once in the channel the molecule binds, at least partially, 
into a hydrophobic pocket, in which molecular motion is 
restricted (Herz et al., 1987). This interaction appears to 
elicit only a small change in the overall conformation of 
the protein (McCarthy & Stroud, 1989).
1.4.1.2 The high affinity channel blocker site
Some of the residues which constitute this site 
were highlighted during investigations aimed at identifying 
the channel forming regions of nAChR subunits (see section 
1.2.2.1) . CPZ (Giraudat et al., 1986a, 1986b and 1989) and 
TPMP (Hucho et al., 1986) both labelled homologous serine 
residues of a., S and r subunits (position 6; Sequence 1.2), 
whilst retaining a 1:1 stoichiometry with the whole 
complex. CPZ also labelled a further serine of the £ 
subunit (position 9) and, in addition, was recently shown 
to label the r subunit (positions 2, 6 and 9, Revah et al., 
1990) . Point mutation studies in mouse muscle receptor 
further emphasised the importance of serine 6; conversion 
to a non-polar residue severely reduced QX-222 affinity 
(Charnet et al., 1990). (This is a local anaesthetic 
showing some structural similarity to CPZ and TPMP; see 
section 1.4.2). The same study suggested that residue 10 
may have a role; mutation from polar to non-polar character 
enhanced QX-222 affinity. Comparison of these sequences 
with other muscle and neuronal subunit data from higher
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species (see Sequence 1.2) suggests that homologous 
residues are present, and thus may interact in these 
receptors in a similar fashion. Thus, all NCIs which act by 
a mechanism of channel blockade, based on their mutual 
competition, appear to operate at a common site, or at 
least overlapping multiple sites; these labelled residues 
(especially the serines at positions 6 and 9) are strong 
candidates for such a site.
1.4.2 Structural features of NCI
The "structural requirements" of nAChR NCI have not 
as yet' been' clearly' defined/ However, analogous data are 
available for a class of glutamate receptors, the n-methyl- 
d-aspartate (NMDA) subtype. Examination of the literature 
suggests that there is some degree of similarity in the 
molecular architecture in the ion channel of NMDAR and 
nAChR. For example, some drugs, notably phencyclidine (PCP) 
and MK-801, appear to antagonize both classes of receptor 
in a pharmacologically similar fashion (ie by channel 
block). In addition, Moriyoshi et al. (1991) have reported 
the cloning of what appears to be an NMDAR subunit, the 
putative M2 region of which has serine/threonine residues 
homologous to those in nAChR (see section 1.2.2.2), and is 
flanked by negatively charged amino acids (which may form 
the equivalent of the "charged rings" postulated to exist 
in nAChR; see section 1.2.2.2).
Using analogues of MK-801, Leeson et al. (1990) 
demonstrated that H-bonding through an amino group was
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energetically the most important interaction of NCI with 
NMDAR. Previously, the presence of a phenyl ring had also 
shown to be vital (Kozikowski & Pang, 1989) . Use of rigid 
PCP analogues indicated that ideally the ring should be 
orientated at 90° to the amino group. Examination of common 
nAChR NCIs structures (See Fig. 1.5) shows most to include 
both features. Those which do not, have mechanisms which 
appear to deviate from pure open channel block. For 
example, hexamethonium, which lacks a phenyl ring, does not 
block NMDAR (Snell & Johnson, 1989). Additionally its 
mechanism at nAChR appears unclear; hexamethonium was 
classified' initially, by pharmacological techniques, as a 
competitive inhibitor (Van Rossum, 1962), though its clear 
voltage dependence favoured a channel block type mechanism 
(Ascher et al., 1979). However, certain features, most
notably a lack of "use-dependence" (Large & Sim, 1986) , 
suggest the need for further reappraisal. Mecamylamine also 
deviates from these structural formulae, and displays a 
considerable variety of mechanisms of action (see section
4.1.2). Particular attention is focussed on its mode of 
action in this project.
1.5 PROJECT AIMS
Much of the mechanistic detail ascribed to nAChR 
function is, as will be obvious from the preceding chapter, 
derived from studies using the easily accessible muscle- 
type receptor, or the a.1 homooligo.mer. The aim of this 
project was to build up a pharmacological profile of the
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g:4£2 nAChR, and to then analyse those observations with 
reference to current models of receptor function.
The a4£2 receptor subtype is the predominant one 
in mammalian and avian brain (see section 3.1.1) , making it 
a good choice for characterisation. It displays some degree 
of similarity with the muscle nAChR, electrophysiological 
recordings display a similarly biphasic desensitisation 
profile for instance. Again in common with the muscle-type 
receptor, it is assumed that this process gives rise to a 
conformation which is able to bind agonists with high 
affinity (see section 3.1.1). Effectors may interact with 
both the-functionally active and desensitised states.
The interaction of agonists and antagonists with 
functionally active nAChR may be investigated by various 
techniques, each with its own advanatges and disadvantages 
(see section 3.2). Receptor expression in Xenopus oocytes 
has proved popular in identifying active subunit 
combinations, whilst previous work in this laboratory has 
used agonist-induced radiolabelled neurotransmitter release 
from preloaded synaptosomes. This study made use of an 
agonist-induced 86Rubidium+ flux into a stably transfected 
mouse cell line expressing a4 and £2 subunits upon 
induction (see section 3.1.2). High affinity radioligand 
binding to both the cell line and to detergent extracts of 
rat brain tissue was used to determine effector interaction 
with the desensitised receptor.
The results are presented. in two sections: the
action of agonists on c*4B2 nAChR first, then the
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antagonists. The final part of this report will then 
attempt to describe these data in the terms of the current 
models of receptor function, thus returning to the primary 
aim of the project.
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Fig. 1.1 Aspects of nAChR structure. (A) Vertical section 
through the native Torpedo nAChR as visualised by helical 
diffraction image reconstruction (resolution 17A; from 
Unwin, 1990). (B) Cross-sectional representations of
Torpedo nAChRs, showing possible subunit arrangements (from 
Kubalek et al., 1987). Note the location of the agonist
binding sites (black triangles) at the ol-t and o1-6 subunit 
interfaces. The "Q'H" and "o^ " designations refer to the 
proposed difference in binding affinites between the two 
agonist sites (see section 1.2.1). (C) Hydropathy plot of
the bovine a-subunit (from Maelicke, 1988) , showing the 
four strongly hydrophobic membrane-spanning domains (Ml- 
M4). (D) Topographical organisation of nAChR subunits (see
section 1.1.3).
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CLEFT
CHANNEL BLOCKER 
SITE (Part)
HYDROPHILIC RING
INTERMEDIATE CHARGED 
RING
CYTOPLASM
Fig. 1.2 Model of the lower (cytoplasmic) portion of the 
ion channel of the a462 nAChR. The model is modified from 
Giraudat et al. (1989) , in which the pore-lining M2 segment 
of the muscle-type nAChR is represented as an a-helix. A 
2:3 stoichiometry of <x:& subunits is assumed (see sections
1.1.1 and 3.3.4). The single letter code is used for the 
amino acid residues.
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Fig. 1.3 Schematic representation of the four superimposed 
rings of amino acids assumed to influence ion channel 
conduction in a41S2 nAChR. The model is modified from 
Changeux (1990). Previous assumptions regarding subunit 
stoichiometry and the conformation of the M2 domain (see 
Fig. 1.2) are maintained here.
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Fig. 1.4 Models of the conformational transitions of 
nAChRs. (A) The "four-state" model (from Changeux, 1990); 
R represents the resting state, and A the active state in 
which the channel is open. Both the I and D states are 
inactive, products of the fast and slow phases of 
desensitisation respectively (see section 1.3.1). (B) The
modified multiple-state model (from Lena & Changeux, 1993); 
D1 and D2 are equivalent to the I and D states of the 
previous model, D3 represents the additional desensitised 
state observed in mutated oil nAChR (see section 1.3.2) .
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Fig. 1.5 Structures of non-competitive inhibtors of 
nAChRs.
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Sequence 1.1 The putative agonist binding domain of (A) 
the Torpedo a subunit, and (B) representative neuronal a 
subunits. The Torpedo sequence, taken from Changeux 
(1990b), indicates the relative positions of the three 
groups of residues implicated in agonist binding by 
affinity labelling studies. Residues marked with a large 
star show unambiguous labelling with DDF; other possible 
sites are indicated with a small star. Residues marked with 
a circle are labelled with MBTA, those with a triangle, 
lophotoxin. The neuronal sequence alignment appears 
courtesy of V. B. Cockcroft.
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Putative agonist binding segments: Torpedo a-subunit
★
VWLPDLVLYN GIWTYO
★  ★
VYYTCCPDTPYL
B Putative agonist binding segments: neuronal a-subunits
rat a2 IWIPDIVLYN 
chick a2 IWIPDIVLYN 
rat a3 IWKPDIVLYN 
chick a3 IWKPDIVLYN 
rat a4 IWRPDIVLYN 
chick a4 IWRPDIVLYN 
rat a5 LWIPDIVLFD 
chick a7IWKPDILLY N
6SWTYD
GSWTYD
GSWSYD
GSWSYD
GSWTYD
GSWTYD
GSWTYD
GSWTYG
K KYDCC
KKYDCC
IKYNCC
IKYNCC
RKYECC
KKYECC
RTDSCC
SFYECC'
AEIYP 
TEIYP 
EEIYQ 
EEIYT 
AEIYP 
TEIYP 
—  WYP 
KEPYP
Sequence 1.2 The Ml and M2 regions of (A) Torpedo nAChR 
subunits, (B) representative neuronal nAChR a subunits and 
(C) representative neuronal nAChR S subunits. The Torpedo 
sequence, taken from Changeux (1990b), shows those residues 
affinity labelled with chlorpromazine (CPZ; circles) which 
constitute the high affinity channel blocker site. Also 
shown are the binding sites of other compounds: quinicrine 
azide (QA; squares) and meproadifen mustard (MM; diamonds) . 
Small dots indicate residues mutated by Imoto et al. 
(1988) . The neuronal sequences appear courtesy of V.B. 
Cockcroft.
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A Torpedo nAChR subunits
M1 M2
a
B
y
6
QEH0LM 
IQR 
IQR 
IRR
KP
KP
KP
YF
LFY
LFY
LFY
FYLPlTBsG-lKjMTLSlgVLLSLTVFLLVIVilLIPSTSSAVP  
p8aG-| KMSLS I©Al{l)AVTVFLLLLA..FYLP 
..YFLP 
..FYLP
t t
QA
aqaggqk!
KVPETSLSVP
QKVPETSLNVP
AESG-EK^STAljgyLLAQAVFLLLTSlQRLPETALAVP
t t t
CPZ
t
MM
B Representative neuronal nAChR a-subunits
rat a2 
chick a2 
rat q3 
chick a3 
rat a4 
chick d4 
rat q5 
chick q7
FYLF SDCG
LPLFY
LPLFY FYLP
FYLF
ITLCISVLLSLTVFLLLITE 
ITLCISVLLSLTVFLLLITE 
TLCISVLLSLTVFLLVITE 
VTLCISVLLSLTVFLLVITE 
VTLCISVLLSLTVFLLLITE 
ITLCISVLLSLTVFLLLITE 
ISLCTSVLVSLTVFLLVIEE 
ISLGITVLLSLTVFMLLVAE
IIPSTSLVIP 
IIPSTSLVIP 
TIPSTSLVIP 
TIPSTSLVIP 
IIPSTSLVIP 
IIPSTSLVIP 
IIPSSSKVIP 
IMPATSDSVP
C Representative neuronal nAChR B-subunits
rat S2 IRRK PLFY. . . . FYLF SOCG-EH MTLCISVLLALTVFLLLIS K IVPPTSLOVP
chick 02 IRRK PLFY . . . . FYLF SDCG^EF MTLCISVLLALTVFLLLIS K IVPPTSLDVP
rat 03 LRRL PLFY . . . . FYLF SDEG-EK LSLSTSVLVSLTVFLLVIE E IIPSSSKVIP
rat 04 IKRK PLFY . .. . FYLF SDCG-EK MTLCISVLLALTFFLLLIS K IVPPTSLDIP
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2 MATERIALS AND METHODS
2.1 MATERIALS
(-) [3H]Nicotine (approximately 75Ci/mmol, 15/zM in 
90% ethanol) , (-) [3H] cytisine (approximately 30Ci/mmol, 30/xM 
in 90% ethanol) and 86Rubidium chloride (approximately 
4mCi/mg in 0.5M hydrochloric acid) were obtained from New 
England Nuclear (Stevenage, Herts., U.K.). A 10 fold molar 
excess of mercaptoacetic acid was added to the [3H] nicotine 
on receipt to reduce reductive degradation of nicotine 
during storage (Romm et al., 1990).
Dihydro-S-erythroidine, MK-801 and phencyclidine 
were gifts from Merck, Sharp & Dohme Research Laboratories 
(Rahwey, New Jersey, U.S.A).
The monoclonal antibodies, mAb 290 and 295 were 
gifts from Dr. P. Whiting (Merck, Sharp & Dohme Research 
Laboratories, Harlow, Essex, U.K.).
All other reagents were obtained from Aldrich 
(Gillingham, Dorset, U.K.), BDH (Poole, Dorset, U.K.), 
Gibco BRL (Paisley, Scotland, U.K.) or Sigma Chemical 
Company Ltd. (Poole, Dorset, U.K.).
2.2 METHODS
For ease of reference, protocols will be grouped 
according to tissue from which the receptor proteins were 
derived (ie either rat forebrain preparations or the
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transfected M10 cell line)
2.2.1 Brain tissue protocols
2.2.1.1 Membrane preparation
Male Wistar rats (200-2509, 12 hour light and
dark cycle with free access to food and water) were killed 
by cervical dislocation then decapitated. The brains were 
removed (minus cerebellum), frozen rapidly and stored at 
-70°C if not required immediately. (Such treatment does not 
significantly alter the number of measurable high affinity 
agonist binding sites, (Benwe.ll £c _BalfourIL985) )-. - - - - - - - -
Membrane preparation followed the protocol of 
Macallan et al. (1988). Breifly, brains were homogenised 
(10% w/v) in 0.32M sucrose (pH 7.4, containing protease 
inhibitors (ImM EDTA and 0.ImM phenylmethylsulphonyl 
fluoride) and 0.1% (w/v) sodium azide) in a pre-cooled
glass-Teflon homogeniser (clearance 0.31mm) by 2x6 up and 
down strokes at 300rpm. The suspension was centrifuged at 
l,000xg for 10 minutes at 4°C (Sorvall RC-5B refigerated 
centrifuge) . The supernatant, SI, was retained on ice, 
whilst the pellet, PI, was washed with 0.32M sucrose (5ml/g 
original wet weight) by resuspension then centrifugation 
(l,000xg, 10 minutes).
The combined supernatants were centrifuged at 
12,000xg for 30 minutes to give the P2 pellet. This was 
washed twice by resuspension in 50mM potassium phosphate 
buffer (see section 2.1; pH 7.4, containing protease 
inhibitors as above) to give a final volume of 2.5ml/mg
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original wet weight, and centrifugation (12000xg, 30
minutes), before final resuspension in 50mM phosphate 
buffer. Aliquots (10ml) were stored at -20°C until required.
2.2.1.2 Triton X-100 extraction of P2 membranes
P2 membranes were centrifuged at 12,000xg for 30
minutes, then resuspended up to half original volume in 
binding buffer (Krebs-HEPES-TRIS, see section 4.2.1). 
Triton X-100 (10% v/v) was added to give a final
concentration of 0.5%.
After continuous stirring for 1 hour at 4°C, the 
suspension was centrifuged at 100,000xg for 45 minutes 
(Beckmann L5-50B Ultracentrifuge, SW50.1 rotor). The 
supernatant, termed the Triton extract, was collected, 
stored at 4°C, and used within a period of 3 days.
2.2.1.3 T3H1 Nicotine binding assays
Tritiated nicotine binding to brain preparations 
was first convincingly demonstrated by Romano & Goldstein 
(1980), using a racemic ligand and rat membranes. The 
protocols for both equilibrium and kinetic binding studies 
shown here, follow those of Lipiello & Fernandes (1986), 
modified for use with Triton extracts.
2.2.1.3.1 Equilibrium studies
The Triton extract was diluted with Krebs-HEPES- 
TRIS buffer, such that the final detergent concentation was 
below 0.1% (unless otherwise stated, see section 4.2.3).
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Triplicate samples (0.25ml, approximately lmg protein/ml) 
were incubated with [3H]nicotine (final concentration lOnM 
for competition assays, 1 to 40nM for saturation assays 
unless otherwise stated) for 30 minutes at room 
temperature, and in the presence and absence of excess 
unlabelled nicotine (ImM) to determine specific binding.
The samples were chilled for 1 hour at 4°C. Incubation was 
terminated by dilution with 3ml ice cold phosphate buffered 
saline (PBS; lOmM potassium phosphate (see section 2.1), pH 
7.4, containing 0.14m sodium chloride and 0.01% sodium 
azide).This was followed by rapid filtration under_vacuum . _ - 
on to a double thickness of Gelman GFA/E glass fibre 
filters presoaked overnight in 0.3% (v/v) polyethyleneimine 
(Bruns et al. , 1983), using a Brandel 24-channel tissue
harvester to separate bound and free radioactivity. The 
filters were further rinsed with 2x3ml PBS; filtration and 
washing were accomplished within 15 seconds. The 
radioactivity retained on the filters was measured by 
liquid scintillation counting (5ml Optiphase scintillant 
per filter), using a Packard scintillation 
spectrophotometer. Binding to P2 membranes was performed in 
a similar manner.
Where the effects of an antagonist on binding to 
P2 membranes were under investigation (see sections 4.3.1 
and 4.3.2), the drug was first dissolved in 95% (v/v)
ethanol, then lOfil added with the radiolabel at the 
beginning of the assay.
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2.2.1.3.2 Kinetic studies
The conditions under which the kinetics of
[3H]nicotine binding to Triton X-100 extracts were assayed 
were similar to those of equilibrium assays, unless 
otherwise stated. Experiments were performed at 4°C. To 
determine the observed association rate (kobg) / C3H] - 
nicotine binding (concentration usually lOnM, but see 
section 4.3.1.1) was determined at intervals up to 3 hours. 
This was later amended, and binding was measured at 1, 2, 
5, 10, 15, 30 and 180 minutes, to focus on the early rapid 
binding phase (see section 4.3.2.1). To measure the
dissociation rate (k ) , extract was equilibrated with 
[3H]nicotine for 3 hours, then excess unlabelled competing 
ligand (ImM (-)nicotine) was added. The radiolabel 
remaining bound at 1, 2, 5, 10, 15 and 30 minutes after
this addition was measured.
2.2.1.4 Protein determinations
Protein concentrations were obtained by the
method of Lowry et al. (1951). Standard curves were 
constructed using a solution of bovine serum albumin (BSA) 
over a concentration range of 50 to 350/zg/ml.
Breifly, duplicate samples (200^1) of BSA
standards or test solutions, diluted up to 1 in 2000 with 
distilled water, were incbated in 1ml alkaline cupric 
tartarate (freshly prepared by mixing 1 volume 1% (w/v)
copper sulphate, 1 volume 2% (w/v) sodium tartarate and 100 
volumes 2% (w/v) sodium carbonate in 0. 1M sodium hydroxide)
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for 10 minutes at 20°C. Folins-Ciocalteau reagent (100/xl, 
diluted 1 in 2 with distilled water) .was added and the 
colour allowed to develop for 40 minutes. Blanks contained 
distilled water in place of the protein solution. 
Absorbance was read at 690nm in a Titertek Multiscan 
spectrophotometer.
The use of Triton X-100 and Krebs-HEPES-TRIS
buffer both interfered with this reaction (see section
4.2.3.2) . The protocol was modified such that the detergent 
and buffer concentrations were the same within each sample, 
a_similar volume-then being added to each-standard: - - -
2.2.1.5 Binding data analysis
[3H]Nicotine binding parmeters to Triton extracts 
were determined from saturation binding assays. The 
dissociation constant (Kd) and the number of binding sites 
(Bmax) were first calculated by the method of Scatchard et 
al. (1949) . These values were then used as first estimates
for an iterative, least-squares curve fitting of the
binding data performed on the SIGMAPLOT 4.1 software 
package (Jandel Scientific, California, U.S.A.). As well as 
being the basis for this more sophisticated calculation of 
Kd and Bmax, the Scatchard transformation of the data
provided information on the homogeneity (or otherwise) of 
the binding sites.
Competition data were analysed by the Hill
transformation, to give the concentration at which the 
competing ligand had half-maximal effect (iC50) . The IC50
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value was used to calculate the inhibiton constant (Ki) was 
using the relationship of Cheng & Prusoff (1974):
Ki = ICS0/(l+[L]/Kd)
Where [L]/Kd is the ratio of concentration of [3H]nicotine 
and its dissociation constant calculated from saturation 
assays. Data were also fitted to asigmoid curve using an 
iterative curve fitting routine on the SIGMAPLOT 4.1 
software package.
2.2.2 Transfected M10 cell protocols
2.2.2.1 Cell culture
Cell stocks were routinely grown up in 175cm2 
platic culture flasks using Dulbecco's modified eagle 
medium (DMEM; 70ml per flask) additionally containing 10% 
foetal bovine serum, additional glutamine (2mM) and 
antibiotic agents (lOOU/ml streptomycin and 100/xg/ml 
penicillin) at 37°C in a humidified atmosphere containing 4% 
(v/v) C02. Maintenance medium also contained 0.5mg/ml G418 
geneticin as a selection agent (see section 3.1.4). This 
was replaced in promotion medium with l^ tM dexamethasone, 
which was noted to bring about a change in cell morphology 
within a day of application, the cells changing from a 
bipolar to more trapezoid form (see Fig. 2.1).
2.2.2.2 Cell harvesting and plating
The tissue culture flasks were gently washed
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twice with 10ml warmed, sterile PBS. This was removed by 
aspiration, and 5ml trypsin-EDTA (0.5g/l trypsin and 0.2g/l 
EDTA.4Na+ in Hank's balanced salt solution) added for 1 
minute, with agitation. DMEM (5ml) was then added, and the 
cells pelleted by centrifugation (500xg, 3 minutes). The
pellet was resupended in 10ml DMEM. A sample (10/xl) of this 
suspension was added to an equal volume of trypan blue 
(0.2% v/v in PBS), and cell numbers determined in a 
haemocytometer. The cells were then either plated for 
experimentation (see following sections) or returned to 
175cm2 flasks for continuous culture.
2.2.2.3 Immunoaffinity immobilisation
This protocol is taken from Whiting et: al.
(1991) . Induced cells were scraped into 1ml PBS, pelleted, 
then resuspended in 500/xl Lysis buffer (50mM TRIS, pH 7.5, 
2 00mM sodium fluoride, 1% (v/v) Triton X-100, 5mM EDTA, 5mM 
EGTA, 5mM iodoacetamide, ImM PMSF) additionally containing 
5mg/ml bovine serum albumin (from a 50mg/ml stock in 1% 
SDS) and 10/zg/ml each of antipain, leupeptin and pepstatin. 
After 15 minutes gentle rotation at 4°C, insoluble material 
was removed by centrifugation (15 minutes, 4°C) . The cell 
extract was pre-absorbed by further rotation for 15 minutes 
with 30(jl1 of goat-anti rat IgG coupled to Sepharose 
(Sepharose-GART). This was removed by centrifugation, and 
the extract rotated for 4 hours at 4°C, with 25jUl of a 
monoclonal antibody, mAb 295, directed against the £2 nAChR 
subunit, coupled to an AFC resin. The resin was pelleted,
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then washed with 5 x 1ml lysis buffer, 5 x 1ml lysis buffer
additionally containing 800mM sodium chloride and 2 x 1ml
lysis buffer, by repeated centrifugation and resuspension.
2.2.2.4 r35S1 Methionine incorporation
After Whiting et al. (1991), confluent M10 cells 
(10cm diameter dishes, 2xl06 cells per dish) were induced 
with ljitM dexamethasone for 16 hours, washed with 3 x 5ml 
methionine-free DMEM, then incubated in the same,
additionally containing 500juCi [35S]methionine, for 6 hours 
at 37°C. After immunoaffinity purification (see section
2.2.2.2), nAChR were eluted from the resin by 2 x 10
minutes incubation in 50[xl 50mM citrate (pH 3.0, containing 
0.01% Triton X-100), followed by 2 minutes in 100^1 
distilled water. The eluate was neutralised with 1M Tris 
(pH 7.5) and concentrated using a Centicon (Amicon) to 
approximately 50jil. This was then diluted with 1ml 
distilled water, reconcentrated and finally lyophilised. 
The subunits were separated by SDS-PAGE. The samples were 
electrophoresed on a 12% (w/v) acrylamide gel in SDS at
35mA for 2 to 3 hours. The gel was then soaked in enhancer 
for 30 minutes, followed by a further 30 minutes in water. 
The gel was dried, and exposed to x-ray film at -7 0°C for 7 
days. To calculate subunit stoichiometry (see section 3.2), 
the gel bands were also excised, dissolved overnight in 1ml 
soluene, and the radioactivity measured by liquid 
scintillation counting.
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2.2.2.5 Radioligand binding assays
2.2.2.5.1 To immunoaffinitv purified receptors
M10 cells were induced by incubation in promotion 
medium containing 1/xM dexamethasone for 3-5 days, and the 
receptor proteins solublised as previously (see section
2.2.2.3). The cell extract was then rotated gently for 16 
hours with sepharose-GART and mAb290 (25/zl and 0.25/xl 
respectively per 10cm dish), instead of the previous two- 
step process (mAb 290 has a similar specificity to mAb295, 
binding^ to _the_ £2 _subunit).. _Sampl.es were routinely pooled,- 
and aliquots taken for binding studies.
Binding assys were performed in triplicate. 
Immobilised nAChR were incubated with either 150/xl (-)-
[3H] nicotine or 50/xl [3H]MK-801 (final concentrations 20nM 
and 5^ iM, repectively) for 30 minutes at 20°C, washed with 3 
x 1ml PBS (including 1% Triton X-100) , and the bound 
radioactivity quantified by liquid scintillation counting. 
Non-specific binding was taken as that bound to an 
equivalent volume of sepharose-GART in the absence of the 
monoclonal antibody.
2.2.2.5.2 To receptors in situ
Cells were plated out (0.29xl06 cells per well, 6- 
well plates) and induced with 1/xM dexamethasone for 3-5 
days. The medium was removed, and each well washed with 2 
x 1ml PBS. Triplicate wells were incubated with [3H]cytisine 
(InM in competition assays, 0.1-5nM for saturation assays),
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or [3H] nicotine (concentration l-30nM), dissolved in Krebs- 
HEPES-TRIS (1ml per well) for 2 hours at 20°C. Total and 
non-specific radioligand binding was determined in the 
absence or presence of excess unlabelled (-)nicotine, 
respectively. Incubation was terminated by the removal of 
buffer by aspiration. Each well was then rapidly washed 
with 4 x 1ml PBS. Washing was routinely accomplished within 
5 seconds. The receptors were then solublised by 
application of 1ml 1M sodium hydroxide overnight. 
Radioactivity was measured by liquid scintillation counting 
(efficiency = 55%).
2.2.2.6 86Rubidium't'influx assays
The protocol of McGee & Liepe (1984) was followed 
with only minor modifications. Breifly, M10 cells were 
plated out (0.29xl06 cells per well, 6-well plates) and 
induced with ljiiM dexamethasone for 3-4 days. On each plate, 
half of the wells were used in the ion-flux assay; [3H] - 
cytisine binding (see section 2.2.2.4.2) was measured in 
the other half. This allowed for the normalisation of the 
flux data by comparison of the levels of surface expression 
of a4£2 nAChRs.
The medium was removed, and each well washed with 
2 x 1ml PBS, and the cells incubated for 15 minutes in 1ml 
balanced salt solution (BSS; 150mM sodium chloride, 1. 2mM 
.magnesium chloride, 5mM potassium chloride, 0.8mM sodium 
dihydrogen orthophosphate, lOmM glucose, 1.8mM calcium 
chloride and 15mM HEPES). The cells were pretreated for 1
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minute with sodium-free BSS (sodium chloride replaced with 
300mM sucrose) additionally containing 2mM ouabain, then 
washed with 2 x 1ml of the same. Each well was incubated 
for 1 minute in 1ml sodium-free BSS additionally containing 
5jLiCi/ml 86Rubidium+ and the combination of agonists/ 
antagonists under investigation. Each well was then rapidly 
washed with 4 x 1ml BSS, and the contents then solublised 
in 1ml 1M sodium hydroxide. Radioactivity was measured by 
liquid scintillation counting (efficiency = 75%).
2.2.3 Chronic chlorisondamine treatment
Two groups of male Wistar rats (240-260g, but 
otherwise as previously; see section 2.2.1.1) were injected 
subcutaneously with either 2ml chlorisondamine solution 
(final concentration 10mg/kg; after Clarke, 1984) or saline 
as controls. Technical assistance was provided by members 
of the Animal House at the University of Bath, who held a 
Home Office license for this procedure. One week after 
injection, the animals were killed by cervical dislocation 
and decapitated. The brains were removed and the cortices 
and hippocampi rapidly dissected. Membrane preparations 
were produced as previously (see section 2.2.1.1).
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Fig. 2.1 Light photomicrographs of M10 cells showing the 
morphology before (A) and after (B) induction with 1pM 
dexamethasone. (Viewed at x100 magnification.)
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3 CHARACTERISATION OF THE tt4S2 nAChR SUBTYPE
3.1 INTRODUCTION
Models of nAChR function rely on data garnered from 
the more accessible, hence more readily studied, muscle- 
type receptors. One of the more notable features of such 
models is the conformational switch nAChR undergo in the 
presence of agonists, and to some extent antagonists (see 
section 1.3.1). Briefly, the receptors shift from a 
"resting" (R) state, in which the affinity for ACh - the 
endogenous agonist - has been measured in the micromolar 
range, to a "desensitised" (D) state. This switch proceeds 
via a transitory "active" (A) conformation in which the 
channel is open. The D state is non-functional, and able to 
bind agonists with higher (nanomolar) affinity. It is 
assumed that neuronal nAChR also broadly follow this scheme 
(see section 1.3.2). However, each subtype appears to 
possess a distinctive pharmacological "fingerprint", as 
reflected in expression studies in Xenopus oocytes for 
example.
The main aim in this section of the project was to 
investigate the pharmacology of a defined receptor subtype 
- the avian a4S2 nAChR - stably expressed in a mammalian 
cell line. (-)Nicotine, ACh, cytisine and (+)anatoxin-a 
((+)AnTX) were chosen as representative agonists. The cell 
line allowed examination of the interaction of the agonists 
with both the R and D states of the receptor with only 
minimal differences in tissue preparation and reaction 
conditions between protocols (see sections 2.2.2.5 and
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2.2.2.4.2 respectively). Agonist affinities for the R 
conformation were measured by their ability to elicit 
86Rubidium+ influx into the cells (see section 3.3.3). For 
the D state, agonist affinity was assayed by competition 
for equilibrium binding of [3H]cytisine (see section
3.3.2.4) .
Before the results are presented, brief backgrounds 
to both the a4£2 nAChR subtype, and the M10 transfected 
cell line will be given (see sections 3.1.1 and 3.1.2 
respectively). In addition, the literature relating to the 
chosen agonists will be reviewed (see section 3.1.3).
3.1.1 Properties of the ot4&2 nAChR subtype
The predominant nAChR immunoaffinity purified from 
brain was shown by amino-terminal sequence determination to 
be composed of subunits corresponding to 0f4 and £2 (Whiting 
et al. . 1987; Schoepfer et al., 1988). Studies of mRNA
levels confirmed that o?4 was the most widely expressed of 
the nicotinic a genes in the brain, whilst £2 was shown to 
be present in all regions examined (Wada et al-/ 1989). 
Coexpression in Xenopus oocytes confirmed that this 
combination of subunits was indeed capable of forming 
functional ligand-gated ion channels (Bertrand et al.. 
1990) . It should be noted that the rat a4 clone has been 
shown to give rise to electrophysiological responses when 
injected alone, though these were comparatively uncommon 
and very weak (Boulter et al., 1987). This has not been so 
for rat £2 (Deneris et al., 1988), or the equivalent avian
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subunits (Ballivet et al., 1988; Bertrand et al., 1990).
The rat a4 gene may be differentially spliced, giving 
rise to two alternative products. These proteins, o?4-l and 
a4-2 differing only at their carboxy-termini (Goldman et 
al., 1987), appear to show little difference in their 
distribution (Wada et al., 1989), or functional properties 
as observed in Xenopus oocytes (Connolly et al., 1992) .
The a4£2 subtype appears to be the major component of 
the high affinity agonist binding sites in the brain. The 
regions in which a4 and £2 are coexpressed coincide with 
those in which high affinity radiolabelled agonist binding 
has been observed (reviewed in Deneris et al., 1991). 
Receptors immunoaffinity purified from chick brain using 
antibodies raised to Electrophorus. bound [3H]nicotine with 
nanomolar affinity (Whiting & Lindstrom, 1986, 1987; see
also section 3.2) and were found to contain the a4 subunit 
(Whiting et al., 1987). Similarly, [3H]ACh binding to
purified nAChR was almost totally depleted by preincubation 
with an anti-a4 monoclonal antibody (Nakayama et al. 1991) . 
Receptors labelled with a variety of tritiated agonists 
were precipitated from a brain extract by antisera to both 
o l4 and £2, though analogous antisera against ot2, o?3, a5 and 
£4 had no effect (Flores et al., 1991). The inactivity of 
the antiserum raised against o?5 is of particular note; a 
recent report (Conroy et al., 1992) has suggested that a5 
can coassemble with oi4 and £2 subunits. However, the 
relatively low abundance of o?5 within the CNS (Wada et al., 
1990) implies that, even if all a5 subunits were present
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with oi4 and £2 , this would only represent a very small 
proportion of the a4£2 receptor population.
3.1.2 The transfected M10 cell line
The M10 cell line stably transfected with chick 0t4 
and £2 subunits expresses surface nAChRs when induced by 
dexamethasone. It thus provides a model system in which the 
biochemical, pharmacological and electrophysiological 
properties of this subtype may all be studied. The 
construction and preliminary characterisation as reported 
by Whiting et al. (1991) are summarised here.
The cDNA clones encoding the chicken a4 and £2 
subunits (pCh26.1 andpCh23.1 respectively) were engineered 
to remove untranslated 5' and 3' regions, then cloned into 
a pMSG derived expression vector additionally including a 
neomycin resistance gene (see Fig 3.1). The subunits were 
cloned into separate constructs at the EcoRl site, then 
cotransfected into mouse Ltk" cell. Levels of nAChR 
expression, as measured by [3H]nicotine binding to 
solubilised and immunoimmobilised receptors (protocol 
analogous to that in section 2.2.2.4.1), was found to 
increase rapidly for 3 days after induction with 
dexamethasone, then stabilise.
[3H]Nicotine binding to immunoimmobilised cells was 
shown to be saturable, and to display an affinity similar 
to that of a4£2 prepared from chicken brain (Kd = 3.2 ± InM 
compared to 3.6 ± 0.3nM respectively). Binding was
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displaced from both M10 and chicken brain receptors by 
cholinergic agonists and antagonists with similar Ki values 
(see Table 3.1).
Table 3.1 Inhibition of [3H] nicotine binding to a 4S2 nAChR 
purified from M10 cells and chicken brain (Whiting et al., 
1991)
Agonists and 
Antagonists
Ki
a4£2 from M10 cells of4S2 from chicken 
brain
Cytisine 0.14 ± 0.03nM 0.14 ± 0.04nM
(-) Nicotine 3.9 ± 2.InM 2.4 ± 0.5nM
Carbachol 0.36 ± . 13juM 0.45 ± 0.12/xM
d-Tubocurarine 25 ± 14/iM 7.7 ± 1. 5/iM
Hexamethonium 0.30 ± 0.06mM 0.16 ± 0.05mM
Mecamylamine >lmM >lmM
Functional data from whole cell voltage clamp 
measurements showed the cell line to respond to ACh (30/xM) 
and to display a characteristic biphasic desensitisation 
(see Fig 3.2A), which mirrors that observed for a4£2 nAChR 
expressed in Xenopus oocytes (see Fig. 3.2B). These 
currents were not influenced by muscarinic agonists or 
antagonists, but were blocked by hexamethonium, d- 
tubocurarine and DHBE.
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3.1.3 The agonists
The three dimensional conformations of the four 
chosen agonists - ACh, (-)nicotine, cytisine and 
( + ) anatoxin-a - are shown in Fig. 3.3. Before moving to 
individual agonists, it may be of value to examine the 
strengths and weaknesses of the experimental systems 
commonly encountered in the literature. It is not the 
practical details of each that are important in this 
context, rather the constraints a given system places on 
the results it generates. It is vital that these 
considerations be borne in mind when examining the data 
which follow.
In the widest sense, it may be argued that binding 
studies are of only limited value in the study of neuronal 
nAChR. It is fair to say that high affinity agonist binding 
is only of relevance to the a4£2 subtype (see section
3.1.1), and even then relates to the non-functional D 
conformation (see section 1.3). However, binding studies do 
provide valuable information regarding receptor density, in 
addition to insights into the mechanisms of receptor-ligand 
interactions.
Functional data - that is, relating to agonist 
affinity for the R state - must also be treated with 
caution. Two questions must always be borne in mind: what 
is the identity of the receptor subtype present, and does 
the experimental system used reflect physiological 
conditions? For example, the expression of nAChR subunit 
combinations in Xenopus oocytes has proved invaluable in
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the delineation of the possible functional receptor 
subtypes. However, the properties of these subtypes may not 
be identical to those in vivo; the membrane environment may 
differ considerably to that of the native receptor, whilst 
any necessary post-translational modification may be 
performed incorrectly, or not at all. In addition, 
functional neuronal nAChR containing more than two 
different subunit types have yet to be demonstrated in the 
Xenopus oocyte expression system, even though recent 
evidence suggests that such receptors occur in vivo (Conroy 
et al., 1992; see section 3.1.1). Such considerations do 
not apply to preparations of neuronal tissue, such as brain 
slices or synaptosomes. In essence the latter are isolated, 
though still functional, nerve terminals, and have proved 
useful in the investigation of neuronal nAChR. However, 
overlapping subunit distributions within the brain often 
leads to heterogeneous receptor populations in both forms 
of tissue preparation; subsequent difficulties may arise in 
subtype identification. This potential heterogeneity may 
also be true of tumour-derived cell lines; the extensively 
used PC12 cell line has been found to contain mRNA encoding 
no less than 6 different nAChR subunits for example (see 
section 1.3.2) .
3.1.3.1 Acetylcholine and (-)Nicotine
In essence, these agonists define this subclass of 
ligand-gated ion channels. So, whilst ACh is the endogenous 
ligand of all cholinergic receptors, it is the rapid
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response to (-)nicotine which distinguishes the ionophores 
- the nAChR - from their G-protein coupled counterparts, 
the muscarinic receptors. Thus it seems appropriate to 
review the actions of these two molecules together.
It is well established that (-) [3H]nicotine and 
[3H]ACh label the same site in rodent brain (Marks et al., 
1986; Martino-Barrows & Kellar, 1987), and that this site 
has subsequently been shown to be the o?4£2 nAChR subtype 
(see section 3.1.1). However, a difference between the two 
agonists in binding affinity is evident. Kd values for (-)- 
[3H]nicotine have been variously reported to be between 2 
and 20nM (Wonnacott, 1987), varying little over a range of 
species; thus, those in rat (9.3nM; Macallan et al., 1988), 
mouse (6nM; Grady et al., 1992) and chicken (4nM; Whiting 
& Lindstrom, 1987) all fall within a similar range. This 
high binding affinity appears enantiomer specific. In a 
series of studies, ( + )nicotine displaced (-) [3H]nicotine 
from brain membranes with between 17 and 180 times less 
potency than did the unlabelled (-)enantiomer (Wonnacott,
1987). (Thus, the use of racemic [3H] nicotine in earlier 
studies yielded rather lower binding affinities than those 
quoted above; for example, Romano & Goldstein (1980), using 
rat membranes, reported a Kd value of 40nM.)
The affinity of ACh for the a4£2 receptor subtype 
may be somewhat lower than that of (-)nicotine. Direct 
comparisons are few (Martino-Barrows & Kellar, (1987) 
reported Kd values of 3.5nM and llnM for (-) [3H] nicotine and 
[3H]ACh binding to rat cortical membranes respectively) ,
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though many workers have reported ACh to be some 1.5 to 8 
times less potent in competing for (-) [3H] nicotine binding 
sites than unlabelled nicotine (Wonnacott, 1987).
In light of the foregoing difference in binding 
affinity to the D state, functional data suggest both 
agonists to have a similar affinity for the R state of the 
a4£2 subtype. Expression studies in Xenopus oocytes rate 
them as equipotent at this subtype (though not at others, 
see Table 3.3). Interestingly, Rapier et al. (1990) also 
implied that the two agonists were of equivalent potency; 
when applied at the same concentration, both elicited 
similar profiles of [3H]dopamine release from rat striatal 
synaptosomes. Grady et al. (1992) using a similar 
experimental approach with mouse tissue, recently reported 
similar EC50 values for (-)nicotine and ACh (480nM and 341nM 
respectively). Though further confirming the similarity in 
potency of the two agonists at this subtype, it should be 
noted that the values themselves are an order of magnitude 
higher than that previously published by Rapier and her 
colleagues (3.8/iM; Rapier et al., 1988)
Aside from the expression studies, data relating to 
other receptor subtypes is scarce. However where they do 
exist, they prove to be as consistent as those for the a4£2 
nAChR. Several studies have used PC12 cells, estimating the 
agonist affinity of the dominant receptor subtype, which 
may be o?3S4 (but see section 1.3.2) . Lukas (1989) measuring 
agonist-induced 86Rubidium efflux from pre-loaded cells, 
estimated EC50 values of 20/iM and 40/xM for (-)nicotine and
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ACh respectively. As with the a4£2 nAChR subtype, the 
oocyte studies have suggested that the two agonists have a 
similar potency at this receptor (see Table 3.2).
Table 3.3 ACh and (-)nicotine responses of neuronal nAChR 
as expressed in Xenoous oocytes,
nAChR subtype ACh EC valuesso
{/XM>
Relative nicotine 
potency (ACh =* l)
c*2S2 - 0. 2e
a2£4 - 0.4®
0'3S2 5 . 6a (354b) 17e
a3S4 158a (30b) le
o?4S2 0.77a,c 1°' 6
a4S4
1800 0. 3e
oil 115d (320f) ~0.2d
References: a - Couturier et al.~ 1990a (chicken) 
b - Cachelin & Jaggi, 1991 (rat) 
c - Bertrand et al., 1990 (chicken) 
d - Couturier et al., 1990b (chicken) 
e - Leutje & Patrick, 1991 (rat) 
f - Amar et al., 1993 (chicken)
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Unfortunately, the two EC50 values given are wildly 
disparate, though at least that of Cachelin & Jaggi (1991) 
resembles the PC12 value. Daly et al. (1991) reported an 
EC50 of 35jiiM for (-) nicotine, using a 22Sodium influx 
protocol, adding further weight to the identification of 
a3£4 as the main PC12 nAChR.
3.3.1.2 Cytisine
Cytisine is a rigid nicotinic agonist found in a 
number of plants of the leguminosae family. Immuno- 
precipitation studies have shown [3H]cytisine to label a4S2 
nAChR (Flores et al., 1991). Furthermore, binding studies 
have suggested it to have a higher affinity for this 
subtype than [3H]nicotine, displacing the latter from brain 
tissue with affinities ranging between 0.3 and 14nM 
(reviewed in Wonnacott, 1987) . Recently, Pabreza et al. 
(1991) showed [3H]cytisine to label a single class of sites 
with a Kd of less than InM. This binding was displaced by 
(-)nicotine, though with an affinity less than that of 
unlabelled cytisine (IC50 values of 8.9nM and 1.2nM, 
respectively).
How this difference in binding affinity between 
cytisine and nicotine relates to functional data is less 
clear. A recent report by Grady et al. (1992) showed 
cytisine and nicotine to be equipotent in eliciting 
[3H]dopamine release from mouse striatal synaptosomes, 
confirming an earlier observation by Rapier et al. (1990) . 
Conversely, Marks et al. (1993) have reported cytisine to
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be very poor at inducing 86Rubidium release from mouse 
striatal synaptosomes; the affinity was low, and the 
magnitude of the induced response did not match that 
generated by other agonists. They concluded that cytisine 
was a "partial agonist". Similarly, cytisine appeared to 
have only low potency at nAChR subtypes which included the 
S2 subunit when expressed in Xenopus oocytes; the o?4S2 
subtype was reported to have a 30 fold preference for 
nicotine (Leutje & Patrick, 1991) . These data also have 
echoes in behavioural studies; Reavill et al. (1990) showed 
cytisine to be a less potent agonist than nicotine in some 
behavioural tests, an observation which could not be 
accounted for simply by differences in their 
pharmacokinetics. An interaction with several nAChR 
subtypes, or differential effects on a single subtype, were 
suggested to be responsible.
3.3.1.3 (+)Anatoxin-a
(+)Anatoxin-a (AnTX), derived from a freshwater 
alga, is a potent agonist of muscle nAChR. Functional 
responses were elicited at (+)AnTX concentrations between 
20 and 200nM, making it almost an order of magnitude more 
potent than ACh (Swanson et al., 1986). Unlike most other 
agonists however, there is only a modest increase in 
affinity for (+)AnTX during the conformational shift of the 
receptor from the R to the D state (see section 3.3.1). 
Thus, in competition binding assays, (+)AnTX was found to 
be only some 3 fold more potent in displacing [125I] a-BgTX
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than ACh (Swanson et al., 1986). The receptor also
demonstrated a marked stereoselectivity for the 
(+)enantiomer; (-)AnTX had a 500 lower affinity than 
(+)AnTX in the previous assay. At high, micromolar, 
concentrations both AnTX enantiomers behave as channel 
blockers at the neuromuscular junction (Kofuji et al., 
1990) .
AnTX also appears to be an agonist of the neuronal 
nAChR, though the data are less complete, and relate to a 
number of subtypes. The nAChR of PC12 cells (see section
1.3.2) have been shown to respond to AnTX; the reported 
affinity was comparatively low (IC50 = 4.5/iM), though the 
racemic agonist was used (Daly et el-/ 1991).In competition 
studies ( + )AnTX displaced both [3H]ACh (Zhang et., 1987) and 
[3H]nicotine (Macallan et al., 1988) from rat brain 
preparations with nanomolar affinities (4.5nM and 0.34nM 
respectively), suggesting interaction with the a4£2 
subtype. (-)AnTX was even less potent, comparatively, than 
at the muscle-type receptor (Ki = 0.39/iM; Macallan et al. ,
1988) . In addition, ( + )AnTX was observed to cause an 
upregulation of [3H]nicotine binding sites (Rowell & 
Wonnacott, 1990) . Interestingly, the concentration of AnTX 
was 60 fold below that of (-)nicotine required to induce a 
similar effect. Behaviourally, Stolerman et al. (1992) have 
recently shown (+)AnTX to produce similar, but not 
identical, effects to (-)nicotine.
The 0f7 (a-BgTX binding) neuronal receptor subtype 
appears to be less sensitive to (+)AnTX than a4S2, though
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it still displays stereoselectivity (for [125I] of-BgTX binding 
to rat brain, ( + )AnTX Ki = 91nM; (-)AnTX, Ki = 21fM;
Macallan et al., 1988). Primary cultures of hippocampal 
neurons (which probably express al subunits) respond 
functionally to ( + )AnTX (EC50 = 3/zM) , where it was found to 
be 10 fold more potent than ACh (Alkondon et al., 1992).
3.2 RESULTS
3.3.2 Equilibrium binding studies
To measure the characteristic high affinity agonist 
binding of the transfected M10 cell a4£2 nAChR (see 
section 3.1.1), a variety of practical techniques were 
tried and evaluated. Each will be described in turn, with 
brief practical notes where necessary, with examples of the 
data each generated.
3.3.2.1 High affinity PHI nicotine binding to 
immunoimmobilised M10 nAChR 
In the preliminary characterisation of the M10 cell 
line, a4&2 nAChR were solubilised, immunoaffinity 
immobilised, and the [3H]nicotine binding parameters 
determined (see section 3.1.2). Following a similar 
protocol to that of Whiting et al. (1991; see section
2.2.2.4.1), non-specific binding, defined as that to the 
Sepharose-GART only, was very low (see Fig. 3.4A); 
Scatchard analysis and iterative curve fitting gave a 
single class of sites, Kd = 2.9 ± 0.InM (mean ± range, n=2, 
see Fig. 3.4B). As the assays used aliquots derived from
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several "pooled" plates of cells, the derived Bmax values 
reflect only indirectly the density of [3H]nicotine binding 
sites (hence receptors) per cell.
3.3.2.2 High affinity T3H1nicotine binding to M10 cell
detergent extracts
M10 cells were extracted with Triton X-100, and 
assayed for [3H]nicotine binding, following a modification 
of the protocol used routinely for rat brain membranes (see 
section 2.2.1.2). Briefly, confluent cells (4x10cm plates) 
were scraped into PBS containing protease inhibitors (5mM 
EDTA, 5mM EGTA, 0.ImM benzethonium chloride, 2mM benzamide 
and 0.ImM PMSF). The cells were pelleted by centrifugation 
(lOOOxg, 2 minutes), then resuspended in 0.7ml Krebs-HEPES- 
TRIS containing 0.5% (v/v) Triton X-100 and protease
inhibitors as above. After continuous agitation for 1 hour 
at 4°C, the suspension was centrifuged at 100,000xg for 45 
minutes. The supernatant was then further diluted 1 in 5 
(to reduce any possible inhibition of radioligand binding 
by the detergent; see section 4.2.1.3.1), and assayed for 
[3H] nicotine binding.
Initial assays demonstrated the presence of high 
affinity [3H]nicotine binding sites within the supernatant 
(see Fig. 3.5). Based on the average levels of radioligand 
binding and estimations of the cell numbers used in each 
assay, it was possible to calculate an approximate number 
of [3H]nicotine binding sites per cell. Assuming there to be 
two agonist sites per receptor, 18700±4500 (mean±SEM; n=3)
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o?4JS2 nAChR per cell were estimated to be present. However, 
this value is likely to be an underestimate; receptor 
recovery during the extraction process is unlikely to be 
100%. Further experiments to define the binding parameters 
of the nAChR in this preparation proved inexplicably 
difficult; in all cases (n=3) levels of specific
[3H]nicotine binding was too low to analyse.
3.3.2.3 High affinity PHI nicotine binding to M10 cell 
membrane preparations
Membrane preparations were produced by a 
modification of the protocol used previously for the 
immunoaffinity immobilisation of the receptor (see section
2.2.2.4.1). Hence, M10 cells were scraped into
solublisation buffer including protease inhibitors
(lml/35mm plate), but lacking Triton X-100. The cells were 
pelleted, then washed with 2xlml PBS by centrifugation and 
resuspension. Each pellet was incubated in 500jiil Krebs- 
HEPES-TRIS, containing [3H]nicotine (final concentration 
20nM) , then washed with 3xlml PBS. Pellets were then 
dissolved in 175jiil Soluene and transferred to 5ml Optiphase 
for scintillation counting.
A large amount of specific [3H]nicotine binding to 
each pellet was observed, though there was considerable 
variation between replicate samples (see Fig. 3.6). This 
was probably due to the compaction of the pellet and 
incomplete resuspension during incubation with the 
radioligand and subsequent washes. Therefore, a further
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variation in the assay procedure was investigated.
3.3.2.4 High affinity agonist binding to intact M10 cell
monolayers
Radioligand binding to monolayers of intact, 
confluent M10 cells was assayed by incubation with Krebs- 
HEPES-TRIS containing either [3H]nicotine (final 
concentration 20nM) or [3H]cytisine (final concentration 
4nM) in the absence and presence of excess unlabelled (-) 
nicotine followed by rapid washing with PBS (see section 
2.2.2.4.2). Whilst initial assays suggested this method 
yielded consistent and highly reproducible data between 
wells, there appeared to be a larger number of [3H]nicotine 
than [3H] cytisine binding sites. This was a curious 
observation; cell numbers were identical in each case, and 
both the [3H] nicotine and [3H] cytisine concentrations used 
were considered to be saturating at this cell type (see 
section 3.1.2) . In addition, when previously uninduced M10 
cells were assayed, they too seemed to have specific 
radioligand binding sites. Once again, more [3H]nicotine 
sites than [3H]cytisine sites were detected (19.2fmol/l06 
cells compared with 1.2fmol/106 cells; see Fig. 3.7).
The use of the immunoimmobilisation assay (see 
section 3.3.2.1) showed that there was no a4£2 nAChR- 
attributable high affinity radioligand binding in M10 cells 
prior to treatment with dexamethasome (see Fig. 3.8), 
confirming the earlier observation of Whiting et al. (1991; 
see section 3.1.3). Thus, the source of any specific
66
radioligand binding to uninduced cells was something of a 
mystery. However a clue probably lies in the relative 
levels of [3H] nicotine and [3H] cytisine binding. During 
their prolonged exposure (90 minutes) to the radioligands, 
some passive movement into the cell might be expected. (-) 
-Nicotine is more lipophilic than cytisine, thus one would 
predict a faster rate of diffusion into the cell plasma 
membranes. Subsequently, higher levels of [3H] nicotine would 
enter the cells, and be retained during the washes and 
counted. The apparent "specific" nature of the labelling is 
probably due to the method used to define the non-specific 
binding. Non-specific radioligand binding is that observed 
in the presence of a large excess of the unlabelled ligand. 
In such circumstances, the rate of passive diffusion of 
nicotine or cytisine into the cells may actually increase 
(as one would assume any passive mechanism to be 
concentration dependent). However, only a fraction of the 
agonist now entering the cells would be radiolabelled 
(unlike in measurements of "total" binding, where only 
radiolabelled ligand is present). Thus, a difference in 
"total" and "non-specific" binding is observed in the 
absence of o;4S2 nAChR.
Recently, it was reported that some non-neuronal 
cell lines, including mouse fibroblasts, displayed 
specific [125I] a-BgTX binding (Chini et al., 1992). It was 
suggested that such binding was linked to the expression of 
the ot5 nAChR subunit. To test for the presence of such 
subunits in the M10 cell line, [125I] a-BgTX (final
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concentration InM) binding to intact, uninduced cells was 
measured. No specific binding was observed on both 
occasions that the assay was performed (see Fig. 3.7).
Cytisine has been reported to have a higher 
affinity for the D-state o'4£2 nAChR (see section 3.1.1.2) . 
This, and the small amount of non-nAChR mediated "specific" 
[3H]cytisine binding noted above, made it the obvious 
radioligand for use in the further characterisation of this 
protocol. The monolayer binding protocol was used for this 
and all subsequent assays. Saturation binding revealed a 
single population of sites: Kd = 3nM, Bmax = 72fmol/l06
cells (n=2; see Fig. 3.9) . This Bmax value is equivalent to 
approximately 22000 nAChR per cell, assuming two 
[3H] nicotine binding sites per receptor. However, this value 
represents only those nAChRs on the upper face of the cell 
monolayer and thus readily accessible to the radioligand; 
any receptors on the lower surface (ie in contact with the 
culture dish), or inside the cells, will not be labelled.
This technique was further adapted to measure the 
affinity of the four chosen agonists for the D-state of the 
a4S2 nAChR, as assessed by their ability to displace 
[3H]cytisine binding in competition assays. The resultant 
curves are shown in Fig. 3.10, whilst the derived assay 
parameters are summarised in Table 3.3.
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Table 3.3 Agonist competition of high affinity [3H] cytisine 
binding to intact M10 cells.
Agonist Ki (nM) Hill number
ACh 6 . 9±2.3 0.39
(-)Nicotine 3 . 2±1.2 0.78
Cytisine 1. 4±0.9 0.72
(+)Anatoxin-a 2.7±0.6 0.95
3.3.3 AGONIST-INDUCED 86RUBIDUM+ FLUX INTO M10 CELLS
The affinities of the four chosen agonists for the 
R-state of the a4£2 nAChR were assessed by means of a 
86Rubidium ion flux assay. At activating concentrations of 
agonist, ligand binding results in a change of conformation 
in the receptor protein. The nAChR transiently passes 
through an "active" state in which its intrinsic cation 
channel is open - thus permitting ion translocation across 
the plasma membrane - before reaching an inactive, 
desensitised conformation (see section 1.3). This 
allosteric modulation of cell permeability forms the basis 
of the ion flux assay. Briefly, confluent monolayers of M10 
cells were incubated in the absence and presence of 
increasing concentrations of each agonist for one minute 
(see section 2.2.2.5). The replacement of the sodium ions 
in the incubation medium by 86Rubidium+, allowed direct 
measurement of the active state of the a4£2 nAChR.
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The protocol of McGee & Liepe (1984) was found to 
produce adequate results without any fundamental 
modification. The resultant dose-response curves were bell 
shaped for all four agonists (see Figs. 3.11 and 3.12). 
This observation may be indicative of rapid receptor 
inactivation at higher agonist concentrations. The rate and 
extent of agonist-induced receptor desensitisation is 
dependent upon agonist concentration (Changeux, 1990). In 
the flux assays described here, induced M10 cells were 
exposed to 86Rubidium+ and the chosen agonist for a uniform 
period (1 minute), regardless of the concentration of the 
latter. Thus, if the mean open time of the transfected a?4S2 
nAChR ion channels was reduced - and the interval between 
channel openings increased - by high agonist 
concentrations, a reduced ion uptake would be observed.
The slopes of the dose-response curves were usually 
steep, both in the rising and falling phases. Whilst this 
was the case for all of the agonists, it was especially 
notable for AnTX. As a result, EC50 values could not be 
calculated (there being only one, occasionally two, points 
between basal and maximal influx), but were estimated by 
eye. As a further consequence of this steepness in receptor 
response, minor variations in assay conditions led to 
shifts in the position in the peak response between 
experiments. This variability is illustrated in Fig. 3.11, 
which shows the four data sets generated for ACh-induced 
86Rubidium+ influx. Basal influx, that observed in the 
absence of any nicotinic agonist, was similar in all four
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assays (4156, 3623, 3520 and 4578cpm/well). Peak height
also showed little variability, being between 202-299% 
basal influx. (Peak responses most often fell into this 
range for all of the agonists assayed; exceptionally values 
as low as 185%, and as high as 600% were observed.) 
However, this peak response occurs between lxlO"6M and 
lxlO'5M. Thus when the data sets for each agonist were 
normalised, the overall dose-response curves are broader 
than those seen in individual assays (see Fig. 3.12). 
Derived EC50 values are summarised in Table 3.4.
Table 3.4 Agonist EC50 values in eliciting 86Rb+ flux into 
M10 cells.
Agonist e c50 (M)
ACh 2.3 ± 1. 7xl0'6 (n=4)
(-)Nicotine 2.7 ± 0. 7xl0"6 (n=5)
Cytisine 3.7 ± 1. lxlO"6 (n=3)
(+)Anatoxin-a 4.8 ± 1. 8xl0'8 (n=4)
3.3.4 THE SUBUNIT STOICHIOMETRY OF THE AVIAN a4£2 nAChR
SDS-PAGE and autoradiography of the [35S] -methionine 
labelled, immunoaffinity purified nAChR from M10 cells, 
revealed two closely migrating doublets with apparent Mr 
50,000 and 75,000 (see Fig. 3.13). These correspond to the 
expected sizes of a4 and £2 subunits (Whiting et al.,
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1987) .
To determine the stoichiometry of receptor 
subunits, the bands were excised from the gel, solubilised 
and the radioactivity present quantified by liquid 
scintillation counting. With the inclusion of a correction 
factor to account for the dissimilarity in the numbers of 
methionine residues present in each subunit (o?4 has 17 
methionines; £2, 13), the ratio o?:£ was calculated to be 
2:3.9 ± 0.2 (mean ± range, n=2). This is greater than the 
expected 2:3 (see section 1.1.1), though consistent with 
previous data from this cell line (Whiting et al., 1991), 
and may reflect the protocol adopted. The purification 
procedure was performed on whole cell detergent extracts 
using the antibody, mAb 295 (see section 2.2.2.1). Though 
raised against the whole receptor, mAb 295 is directed 
against the £2 subunit. Thus, the isolation of subunits 
incorporated into partially assembled nAChRs may contribute 
to the ratios observed, as could the aberrant assembly of 
homooligomers, if it occurs.
Also of note was the consistent appearance of a 
receptor associated band in the immunopurified preparation, 
with an apparent Mr 43,000. This may be an unglycosylated 
subunit (Whiting et al., 1991), or possibly actin. However, 
the demonstration of the presence of the "43 kD protein" in 
mouse fibroblasts (Musil et al., 1989), and the close 
association of that protein with muscle-type nAChR (see 
Fig. 1.1A) , may make this chance observation one of great 
interest.
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3.4 DISCUSSION
The range of neuronal nAChR subunits thus far 
cloned implies the existence of multiple receptor subtypes. 
Whilst only partially characterised, the strong homology 
that neuronal subunits show with those of the muscle-type 
receptor suggests that the two groups share a common 
functional basis (see section 1.3.2). Muscle-type nAChRs 
are able to adopt several discrete conformational states, 
each of which has its own properties (see section 1.3.1). 
Whilst a spontaneous process, the interconversion of the 
receptor between these states may be modulated by a variety 
of small ligands; it is this which forms the basis of 
receptor function. Thus, when an agonist binds to the 
receptor, it promotes a conformational change which 
ultimately give rise to the desensitised state. As this 
shift from the R- to D-state proceeds, the nAChR may go 
through several transitory, intermediate states. In one of 
these (the A-state), the receptor's intrinsic cation 
channel is permeable.
The M10 cell line, expressing the transfected avian 
0(4132 nAChR, has been used as a model system in the 
investigation of agonist potencies for this neuronal 
receptor subtype. The affinities of four representative 
agonists - ACh, (-)nicotine, cytisine and (+)anatoxin-a - 
for the R- and D-states of the receptor have been measured 
by means of a 86Rubidium+ influx assay and high affinity 
binding studies respectively.
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3.4.1 ACh and (-)nicotine
[3H]Nicotine was used initially to monitor the 
expression of a4£2 nAChR in the M10 cell line. Various 
techniques were used; whilst high-affinity binding was 
always detectable, it was not always possible to measure 
its parameters. The similarity between the [3H] nicotine 
binding to immunoimmobilised receptors in this study and 
elsewhere has already been commented upon (see section
3.2.1.1). [3H]Nicotine binding to the o?4S2 nAChR of intact
M10 cells proved problemmatical. Large amounts of non-nAChR 
dependent specific binding was detected in uninduced cells 
(see section 3.2.1.4), and prevented the generation of any 
meaningful binding parameters from saturation assays (data 
not shown). This was not the case with [3H] cytisine (see 
section 3.2.1.1), and may be related to the relative 
lipophilicity of the two radioligands. In competition 
studies against [3H]cytisine, (-)nicotine has about a two­
fold higher affinity than ACh, whilst both have a lower 
affinity than cytisine; this fits well with values cited in 
the literature (see section 3.1.1)
The affinities of ACh and (-) nicotine for the R- 
state, as measured in the ion flux assay, are very similar 
(see Table 3.4). As with the binding data, this corresponds 
well with the literature. In addition, the micromolar 
affinities are within the range of reported EC50 values from 
different experimental systems (see section 3.1.1). 
However, probably of greater significance is the difference 
in agonist affinity between the R- and D-state. Whilst the
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a4£2 nAChR has been assumed to undergo an increase in 
agonist affinty upon desensitisation, based upon analogy 
with the muscle-type receptors (see section 1.3.1), this 
study represents the first quantitative demonstration of 
this phenomenon in a single, model system.
3.4.2 Cvtisine
In saturation binding studies to intact M10 cells, 
the Kd for [3H] cytisine binding (3nM) was slightly higher 
than might have been predicted from Pabreza et, al. (1991) , 
who reported a value of less than lnM. However, this may 
reflect a difference in the species from which the receptor 
was derived (chick versus rat), or in the assay techniques 
employed. In the competition binding assays, where a direct 
comparison of agonist affinities for the D-state were made, 
cytisine was found to have a higher affinity than (-)- 
nicotine. This difference was again lower than might have 
been predicted (for example, compare Table 3.1 with Table 
3.3) .
With regard to the functional assays, it is 
difficult to reconcile the data presented here with those 
from the literature for the action of cytisine at o:4S2 
nAChR (see section 3.1.3.2). In the ion flux assays, the 
affinities of cytisine and (-)nicotine for the R-state were 
similar (see Table 3.4). More interestingly, the cytisine- 
induced 86Rubidium+ influxes were quantitatively 
indistinguishable from those produced by application of any 
of the other chosen agonists (see Fig. 3.11). The possible
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molecular basis of the differences in cytisine efficacy 
reported here and in the literature are discussed in 
section 5.2.
3.4.3 (+)Anatoxin-a
(+)AnTX is an extremely potent agonist of the o'4£2 
nAChR, with an affinity for the R-state some 50 fold higher 
than that of ACh and (-)nicotine (see Table 3.5). There is 
little in the literature relating to the potency of (+)AnTX 
at this nAChR subtype (see section 3.3.1.3), thus it is 
difficult to comment. The EC50 value reported here is within 
the range of concentrations which gave functional responses 
at muscle nAChR, though the relevance of this is 
questionable. The upregulation study of Rowell & Wonnacott 
(1990), which implied a 60 fold difference in the 
affinities of ( + )AnTX and (-) nicotine, provides some 
indirect corroboration. Thomas et al. (1993) recently 
reported that (+)AnTX elicited [3H]ACh release from rat 
hippocampal synaptosomes with an EC50 of 1.4xlO"7M.
In competition binding studies using [3H]cytisine 
and the M10 cells (see section 3.3.2.4), ( + )AnTX was found
to have an affinity greater than that of ACh and (-)- 
nicotine, but below that of cytisine (see Table 3.3). More 
interestingly, the increase in affinity associated the 
shift from the R- and D-states (see section 3.1) is very 
small; this again echoes the muscle-type nAChR data (see 
section 3.3.1.3). In addition, the Hill number for (+)AnTX 
competition was found to be higher than those of the other
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agonists (see Table 3.3) . Whilst the value was still below 
1, the relative increase in steepness of the curve reflects 
that seen in the ion-flux assays; (+)AnTX-induced dose- 
response curves were notably steeper than those of other 
agonists.
The distinctive features evident in the interaction 
of ( + )AnTX with a4£2 nAChR - the small shift in agonist 
binding affinty with desensitisation, and the steep dose- 
response curves - may reflect a subtle variation in the 
mechanism of agonist-induced receptor activation. This is 
discussed further in section 5.2.
3.4.4 Summary
The interaction of the o?4S2 nAChR with agonists was 
investigated using the transfected M10 cell line as a model 
system. Of the four agonists used in this study, three - 
ACh, (-)nicotine and cytisine - were found to elicit 
functional responses in the 86Rubidium+ influx assay when 
present in micromolar concentrations. The same agonists had 
nanomolar binding affinty in [3H]cytisine competition 
assays. These data suggest that, like the muscle-type 
nAChR, the a4S2 receptor subtype desensitises upon extended 
exposure to agonists, and that this is accompanied by an 
increase in agonist affinity. (+)AnTX proved to be 
exceptional in its potency in the functional assay system, 
yet displaced [3H] cytisine with an affinty similar to the 
other agonists. This, and the steepness of the ( + )AnTX- 
induced dose-response curves, points to a distinctive
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mechanism of receptor activation by this agonist.
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Fig. 3.1 Transfection vectors used in the preparation of 
the M10 cell line (from Whiting et al.; 1991).
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Fig. 3.2 Comparison of agonist-induced whole cell current 
recordings from (A) induced M10 cells (from Whiting et al., 
1991) and (B) Xenopus oocytes expressing chick ce4S2 nAChR
(from Bertrand et al., 1990).
80
Fig. 3.3 Energy minimised structural models of (A) ACh, 
(B) (-)nicotine, (C) cytisine and (D) (+)anatoxin-a.
Structures were provided courtesy of P.Thomas, and were 
built using the HYPERCHEM modelling package (Autodesk Inc., 
California, U.S.A.). Individual atoms are represented as 
colour coded van der Waals spheres (white - hydrogen; pale 
blue - carbon; dark blue - nitrogen; red - oxygen).
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Fig. 3.4 [3H]Nicotine binding to innnunoimmobilised or4£2
nAChR from the transfected M10 cell line. Confluent M10 
cells were induced for 3 days with 1/xM dexamethasome. After 
scraping, a4£2 nAChR were solubilised in buffer containing 
Triton X-100 (1% v/v). Insoluble cell debris was removed by 
centrifugation, and the supernatant incubated with
Sepharose-GART and mAb 290 (25fxl and 0.25/xl per 10cm dish 
respectively). The immunoimmobilised nAChR were washed by 
centrifugation and resuspension, then aliquoted. Aliquots 
were incubated with [3H]nicotine (final concentration 1- 
20nM) to determine total binding (•). Non-specific binding 
(O) was taken as being that to Sepharose-GART only. 
Representative binding data (A) and Scatchard
transformation (B) from a single experiment are shown. Each 
point represents the mean of duplicate samples (the 
standard deviation too small to show up) . The Kd was 
calculated to be 3.0nM.
83
AE
CL
X>
T3
C
o
-O
<D
C
oo
r-O
20000
15000
10000
5000
0 5 10 15 20 25
[ H jN icotine concentration (nM)
B
TD
C
ZJo
_Q
0
C
oo
100
80
60 40
30 -
40 20 -
20 CD
[ H]Nicotine bound (fmol)
0 5 10 15 20 25
[ H jN icotine concentra tion (nM) 
84
E
Cl
~o
c
Z5
o
_Q
CD
C
~o
u
z
X
fO
Fig. 3.5
M10 cells. Confluent M10 cells were scraped into PBS 
(3ml/l00mm dish; 2xl06 cells) containing protease 
inhibitors, and pelleted. The cells were resuspended in 
Krebs-HEPES-TRIS containing 0.5% (v/v) Triton X-100.
Insoluble cell debris was removed after 60 minutes by- 
centrifugation, and the supernatant diluted 1 in 5 to 
reduce detergent concentration. Serially diluted samples 
were incubated with [3H]nicotine (final concentration 20nM) 
in the absence and presence of excess unlabelled (-)- 
nicotine to determine total (i) and non-specific (O) 
binding respectively. Specific binding (I) was calculated 
as the difference between the two. Data from a single 
experiment are shown, each point being the mean of 
triplicate samples.
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Fig. 3.6 [3H] Nicotine binding to M10 membrane
preparations. Confluent M10 cells were scraped into PBS 
(lml/60mm dish; 6xl05 cells) containing protease inhibitors, 
pelleted, and washed twice by centrifugation and 
resuspension. The membranes (500/xl)were then incubated with 
20nM [3H] nicotine in either the absence or presence of 
excess (ImM) unlabelled (-)nicotine to determine total and 
non-specific radioligand binding. Data represent the mean 
± SEM of three dishes for each condition.
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Fig. 3.7 Radioligand binding to uninduced, intact M10 
cells. Confluent, but uninduced, M10 cell monolayers were 
incubated with [3H]cytisine (final concentration 5nM) , 
[3H] nicotine (20nM) or [125I] O'-BgTX (InM) for 90 minutes 
( [3H] cytisine or [3H] nicotine) or 180 minutes ( [125I] a-BgTX) 
in the absence or presence of excess unlabelled ligand to 
give total and non-specific radioligand binding 
respectively. Each column represents the mean ± SEM values 
of specific radioligand binding from four ( [3H] cytisine and 
[3H] nicotine) or two ( [125I] o'-BgTX) separate determinations.
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Fig. 3.8 Comparison of specific [3H] nicotine binding to mAb 
290/Sepharose-GART after incubation with induced and 
uninduced cells. Immunoaffinity purification and subsequent 
[3H] nicotine binding were performed as shown previously (see 
Fig 3.3). Data are the mean ± range from two 60mm dishes 
(7xl05 cells), expressed as dpm (open columns) and fmol 
(shaded columns) per plate. ( [3H]Nicotine binding to an 
equivalent volume of Sepharose-GART to that used in the 
immunoaffinty purification is also shown; this represents 
non-specific binding.)
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Fig. 3.9 [3H]Cytisine binding to intact M10 cells. Three
days after induction with IfiM dexamethasone, M10 cells were 
washed with PBS (3x2ml per 35mm dish) and incubated in 
triplicate with [3H]cytisine (final concentration 0.1-5nM) 
in the absence and presence of excess unlabelled (-)- 
nicotine to determine total (•) and non-specific (O) 
binding. Specific binding (I) was calculated as the 
difference between the two. Representative binding data (A) 
and Scatchard analysis (B) from a single experiment are 
shown (Kd = 3 . InM; Bmax = 80fmol/106 cells) .
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Fig. 3.10 Competition with [3H] cytisine by (A) ACh# (B)
(-)nicotine, (C) cytisine and (D) (+)anatoxin-a for high
affinity binding to intact M10 cells. [3H]Cytisine binding 
to induced M10 cells was measured in triplicate in the 
absence and presence of increasing concentrations of each 
of the agonists. Each point represents the mean ± SEM of 3 
separate determinations.
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Fig. 3.11 Acetylcholine-induced 86Rb+ flux into M10 cells.
86Rb+ influx was measured in triplicate wells (35mm; 2.5x10s 
cells) in the absence and presence of increasing 
concentrations of ACh, 3 or 4 days after induction of the 
M10 cells. Data were normalised by to the levels of 
specific [3H]cytisine binding in each well. For comparative 
purposes, data were then adjusted such that the basal 
86Rubidium+ influx (ie that in the absence of ACh) matched 
the mean value of the range observed over the four 
individual assays (dotted lines). Data are presented in 
both cpm/well (left-hand column), and as a percentage of 
peak response (right-hand column). As each data set is from 
a single experiment, each point represents the mean of 
triplicate samples.
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Fig. 3.12 Dose response curves of agonist-induced 86Kb+ flux 
into M10 cells. 86Rb+ was measured in triplicate wells (35mm; 
2.5xl05 cells) in the absence and presence of increasing 
concentrations of (A) (-)nicotine, (B) cytisine or (C)
( + ) anatoxin-a, 3 or 4 days after induction of the M10 
cells. Within individual assays, data were normalised to 
the levels of specific [3H]cytisine binding in each well. 
The main figure represents the meaned and normalised data 
for 3 or 4 separate determinations; the inset, a 
representative assay.
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Fig. 3.13 Subunit composition of transfected M10 cell 
nAChR. Confluent M10 cells were induced for 16 hours with 
1)jlM  dexamethasone, washed and then incubated for a further 
6 hours in methionine-free DMEM additionally containing 
[35S]methionine (500pCi/1Ocm diameter dish). The labelled 
nAChR were solublised, immunoaffinity purified, then 
separated by SDS-PAGE (12% w/v acrylamide gel). Results 
were visualised by autoradiography.
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4 THE INTERACTION OF NCI WITH NEURONAL nAChR
4.1 INTRODUCTION
The actions of four antagonists - one competitive 
(dihydro-S-erythroidine) and three non-competitive
(me c amyl amine, MK-801 and chlorisondamine) - on the a4£2 
nAChR were investigated. Their effects both on high 
affinity [3H]nicotine binding (see below), and agonist- 
induced 86Rubidium+ flux into the M10 transfected cell line 
were studied.
A report by Takayama et al. (1989) showed NCI to 
affect the binding parameters of [3H]methyl-carbamylcholine 
(an alternative radioligand to [3H]nicotine in binding 
assays, Boksa & Quirion, 1987) to rat brain membrane 
preparations, by performing saturation assays in the 
presence of the antagonist of interest. Such an observation 
emphasises the allosteric nature of the nAChR; interaction 
with a ligand at one site may affect other, more distant 
regions. Whilst the effect of agonist-induced 
conformational change on NCI binding is readily appreciated 
(for example, in exposing the channel blocker site), the 
reciprocal action was, until recently seldom considered. 
Here, these observations have been studied more thoroughly 
using detergent solubilised receptors from P2 membranes 
(see section 2.2.1.2) . The removal of a large proportion of 
the membrane lipid ' prevented it from acting as an 
"unstirred layer" in the kinetic binding studies (see 
section 4.2.2 . 2) .
The interactions of these antagonists with both
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muscle- and neuronal-type nAChR as reported in the 
literature are reviewed first, followed by the results of 
this study.
4.1.1 Pihydro-S-ervthroidine
Dihydro-S-erythroidine (DHSE) is a more active 
derivative of S-erythroidine, an alkaloid isolated from the 
seeds of several Erythrina species. It is a secondary amine 
(see Fig. 4.1), and is unusual in that conversion to its 
salt reduces its potency as an antagonist (Wonnacott, 
1987b). Early investigations established DHSE as a 
competitive neuromuscular blocking agent (reviewed in 
Wonnacott, 1987b), though more recent evidence suggests 
antagonism at muscle-type nAChR may include a small non­
competitive element (Jones et al., 1986).
DHSE is a potent nicotinic antagonist in the 
central nervous system, and has been shown to attenuate 
receptor responses to a variety of agonists. For example, 
[3H]dopamine release from striatal synaptosomes in response 
to 1/xM (-)nicotine or cytisine was reduced to 30 to 40% of 
control values by 0.5/xM DHSE (Rapier et al., 1990). At a 
similar concentration, DHSE was shown to shift the dose- 
response curve of a4S2 nAChR expressed in Xenopus oocytes, 
increasing the apparent EC50 value of ACh over four fold 
(2.9/iM, compared with 0.7/xM in the absence of DHSE; Valera 
et al., 1992). This is indicative of a competitive
antagonist.
DHSE, where tested, appears to act at all nAChR
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subtypes, though it may do so with a gradation of 
potencies. Using whole cell current recordings, Alkondon 
and Albuquerque (1993) were able to divide a population of 
cultured hippocampal neurons into a number of "types" on 
the basis of the electrophysiological properties of their 
nAChRs. The majority of neurons ("type IA" currents, oil 
nAChR) were affected only by DHSE at concentrations in 
excess of 10/iM. However, a small population of cells were 
highly DHSE-sensitive; lOOnM DHSE was found to achieve 
almost complete blockade. These "type II" currents were 
proposed to correspond a4S2 nAChR. A (smaller) difference 
in DHSE affinity for the two receptor subtype is evident 
from high affinty binding data. Thus, Rapier et al. (1990) 
showed approximately a 20 fold difference in the affinty of 
the antagonist between [3H] nicotine and [125I] O'-BgTx binding 
sites (1.3/xM compared with 27ptM respectively). 
Interestingly, [3H] DHSE has been shown to bind to two 
populations of sites in rat cortical membranes with 
dissociation constants of 4nM and 22nM (Williams & 
Robinson, 1984). Perhaps these correspond to the two ligand 
binding sites examined by,Rapier at al. (1990)?
In contrast, Lukas (1989) has suggested DHSE to 
be only a very weak, but equipotent, antagonist of both 
muscle and ganglionic nAChR. In 86Rubidium+ efflux studies 
using TE671 and PC12 cell' lines, IC50 values were reported 
to be 2mM and ImM, respectively.
4.1.2 Mecamvlamine
Whilst mecamylamine has been extensively used as 
a central nicotinic antagonist (due to the ease with which 
it crosses the blood-brain barrier), the molecular basis of 
this action remains ill-defined. It would appear that as 
well as interacting with NMDAR (Snell & Johnson, 1989; see 
also section 1.4.2), mecamylamine exhibits different 
mechanisms of action according to the nAChR subtype with 
which it interacts. At the neuromuscular junction (where 
nAChR contain the al agonist- binding subunit - but see also 
section 1 .2 .1), the mechanism of mecamylamine antagonism 
appeared to be voltage dependent channel block (Varanda et 
al., 1985). Conversely, at ganglia (which express high
levels of oi3, oil and £4 subunits (Listeraud et al. , 1991)) , 
its action has been claimed to be one of voltage 
independent competitive inhibition (Ascher et al., 1979). 
Bennet et al. (1957) showed that the effects of 
mecamylamine and hexamethonium at ganglia could be readily 
distinguished; a partial blockade by hexamethonium rapidly 
increased to a total one upon repetitive stimulation; this 
was not a feature of mecamylamine1 s action. This lack of 
"use-dependency" was confirmed electrophysiologically by 
Gurney & Rang (1984) , and implied that mecamylamine did not 
act as a channel blocker. Yet in PC12 cells, mecamylamine 
was shown to displace [3H]H12-HTX (Daly et al., 1991), 
suggesting action at the channel blocker site (see section
1.4.1.2). The a4&2 nAChR expressed in Xenopus oocytes was 
blocked by mecamylamine. Although its inhibitory action
required agonist activation, it was found to be voltage 
independent (Bertrand et al.,,-1990). These observations 
suggest a binding site inaccessible when the receptor is in 
the resting conformation, yet not deep within the ion 
channel itself.
4.1.3 MK-801
Originally reported as an NMDAR antagonist (Wong 
et al. . 1986), it is now apparent that the anticonvulsant 
MK-801 also interacts with nAGhR. Inhibition of NMDAR by 
MK-801 is strongly voltage dependent and effective only 
when MK-801 is applied with agonist (Heuttner & Bean, 
1987) , suggesting an open channel block mechanism. The mode 
of action at nAChR appears similar in all reports in which 
mechanism was investigated. For example, in frog 
neuromuscular junction, muscle twitch responses were 
blocked and the frequency and mean channel open time of 
nAChR, analysed by the patch clamp technique, reduced 
(Ramoa et al., 1990). A similar voltage dependent block of 
ACh-evoked currents was observed in bovine chromaffin cells 
(Halliwell et al., 1989). Presynaptic nAChR in rat 
hippocampus were functionally blocked by MK-801, though 
further delineation of the mechanism was not possible with 
the technique employed (Ramoa et al., 1990) . Additional to 
these functional data, biochemical studies indicate that 
MK-801 is capable of displacing both [3H]PCP (Kavanaugh et 
al., 1989) and [3H]H12-HTX (Ramoa et al., 1990) from Torpedo 
membrane preparations. As both radioligands act as open
channel blockers, they are assumed to bind to a specific 
site within the ion channel (seesection 1.4.1.2).
4.1.4 Chlorisondamine
The molecular aspects of chlorisondamine 
interaction with nAChR have received little attention in 
studies other than those using invertebrate-based assay 
systems (see Lingle 1983, for example). Investigators have 
focussed instead on the long term antagonism of central 
nicotinic mechanisms observed in behavioural studies. For 
example, after a single intra-cerebroventricular (Clarke & 
Kumar, 1983; Reavil et al., 1986) or subcutaneous (Clarke, 
1984) injection of chlorisondamine, significant effects 
were noted on different behavioural parameters for periods 
of up to 5 weeks. The efficacy of the latter form of 
administration is particularly surprising; chlorisondamine 
is a bis-quaternary ammonium salt (for structure, see Fig.
4.1) , and as such, would not be expected to cross the blood 
brain barrier.
In mechanistic terms, Van Rossum (1962) viewed 
chlorisondamine as a "typical non-competitive ganglionic 
blocking agent". At frog neuromuscular junction, Neely & 
Lingle (1986) showed the drug to behave as an open-channel 
blocker, with some interesting additional features. 
Recovery from blockade was slow, and subsequent responses 
failed to match those observed before chlorisondamine 
treatment. This was irrespective of any changes made in 
agonist application or holding potential during the
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recovery phase. Curiously, in binding studies using 
membranes prepared from Torpedo electric organ, Daly et al.
(1991) showed that chlorisondamine had little ability to 
inhibit either [125I] a-bungarotoxin or [3H]Hl2-HTX binding, 
suggesting no preference for either the agonist or channel- 
blocker binding site.
4.2 RESULTS
4.2.1 OPTIMISATION OF [3H1 NICOTINE BINDING TO TRITON 
X-100 EXTRACTS OF P2 MEMBRANES
The choice of a detergent extract instead of 
membrane preparation forced a re-examination of the binding 
assay conditions used previously, and an evaluation of 
their suitability in these circumstances.
4.2.1.1 Buffering system
A recent report by Romm et al. (1990) showed that 
the inclusion of 200mM TRIS in the incubation buffer 
reduced non-specific [3H] nicotine binding to mouse brain 
membranes. TRIS, however, is incompatible with a phosphate 
buffer, so its adoption , would necessitate a change in 
buffering systems. [3H]Nicotine binding to Triton X-100 
extracts of rat brain membranes prepared in three buffers 
was compared:
(i) Standard 50mM Phosphate (pH 7.4)
(ii) Krebs-HEPES (pH 7.4.)
(iii) Krebs-HEPES-TRIS (as (ii), but with 200mM 
TRIS)
104
r
Non-specific binding, as a proportion of the 
total, varied between 32 to 55% in comparative assays. In 
all cases however (n=3), non-specific binding was reduced 
by approximately 25% on the inclusion of TRIS in a 
statistically significant fashion (p<0.05; see Fig. 4.2); 
in its absence, little difference between the levels of 
non-specific binding in the two buffering systems was 
observed. Krebs-HEPES-TRIS was therefore adopted in 
subsequent binding assays.
4.2.1.2 Filters
Lippiello & Fernandes (1986), in their use of the 
Brandel cell harvester, separated membrane-bound [3H] - 
nicotine from unbound radiolabel on two thicknesses of 
Gelman GFA/E glass fibre filters. . However, in these 
studies, predominantly performed on Triton X-100 extracts, 
this grade of filter may not have been optimal for the 
solubilised proteins. The retentive properties of three 
filter types, presoaked in 0.3% PEI (see section
2 .2 .1 .3.1), were compared:
(i) Gelman GFA/E
(ii) Whatman GFB
(iii) Whatman GFC
(Due to a difference in thicknesses, only one layer of GFB, 
compared with two layers of GFA/E and GFC, was used.)
Results indicated no significant differences in 
the levels of specific binding retained by the three filter 
grades when using Triton extract (see Fig. 4.3A). However,
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GFA/E filters retained the lowest values of non-specific 
[3H]nicotine binding, both in absolute terms, and as a 
proportion of the total (see Fig. 4.3B). Consequently, 
GFA/E filters were used in all subsequent [3H] nicotine 
binding assays to Triton extracts.
4.2.1.3 Effects of Triton X-100
4.2.1.3.1 On (-) T3H1 nicotine binding
Membrane proteins, including nAChR, were 
solubilised initially by treatment of P2 membranes with 1% 
(v/v) Triton X-100. After centrifugation (see section
2.2.2), [3H]nicotine binding to both supernatant and pellet
was assayed. The sum of these was much lower than the [3H] - 
nicotine binding to a comparable, but untreated, P2 
preparation (see Fig. 4.4A). However, there appeared to be 
a small increase in the number of binding sites in the 
supernatant (or, "Triton extract") upon dilution with 
buffer. This suggested some sort of reversible interference 
with radiolabel binding (it being argued that the pre- 
soaking of the glass fibre filters in 0.3% PEI minimised 
the loss of solublised labelled nAChR during washing). 
Triton X-100 appeared to be responsible; [3H]nicotine 
binding to P2 membranes in the presence of increasing 
concentrations of detergent was reduced in a seemingly 
dose-dependent manner (see Fig. 4.4B). (It is likely that 
the lack of [3H]nicotine binding reported by Whiting & 
Lindstrom (1986) in the preliminary stages of their 
purification of the chick a4S2 nAChR was also due to a high
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(2%) Triton concentration.) A similar experiment was 
performed using Triton extracts at affixed protein 
concentration, but in the presence . of increasing 
concentrations of Triton X-100 (see Fig. 4.5). Severe 
attenuation of [3H] nicotine binding was again evident at the 
higher concentrations of detergent, although in this assay, 
there appeared to be little or no reduction in binding at 
0.1% Triton or below. Consequently, in subsequent assays 
the extract was diluted such that detergent concentrations 
were 0.1% or less. Under these conditions,- the parameters 
of [3H]nicotine binding (most importantly, the affinity) 
were similar to those observed in P2 membranes (see Fig. 
4.6 and section 4. 2.2.1).
Although the recovery of P2 protein in the Triton 
extract varied (73±9%; mean±SEM, n=9), the use of 0.5% and 
1% Triton were found to yield similar amounts of protein 
(extraction of identical membrane preparations with 0.5% 
and 1% Triton yielded protein recoveries of 55% and 53% 
respectively). Adoption of the lower concentration in all 
further extractions allowed the necessary dilution of the 
detergent, whilst retaining the protein concentrations 
which earlier experiments with membrane preparations showed 
to be optimal in binding studies (l-2mg/ml, data not 
shown) .
4.2.1.3.2 On protein determinations
Triton X-100 and HEPES both give positive 
reactions with Lowry reagents in the absence of protein.
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This causes an over estimation of protein concentration if 
the standard protocol is followed. As a consequence, this 
leads to errors in the interpretation of binding data. This 
is exemplified in Fig. 4.7 in which a BSA standard curve 
was assayed by the Lowry method in the presence and absence 
of Krebs-HEPES-TRIS and Triton. At the lower end of the 
scale (comparable with tissue samples) the presence of 
buffer and detergent increased readings by 25-50%. 
Modification of the assay (ie standardising 
buffer/detergent concentrations in samples and BSA 
standards; see section 2.2.4) eliminated this source of 
error.
4.2.1.4 Effect of ethanol on [3H1nicotine binding
All the antagonists tested for an effect on [3H] - 
nicotine binding were first dissolved in ethanol (see 
section 2.2.3) . To examine any possible interaction of the 
solvent itself with nAChR, [3H]nicotine binding at a range 
of concentrations (1, 15 and 40nM) and in the presence and 
absence of 10/zl 95% (approximately lOOmM) ethanol was
assayed. No significant differences in radioligand binding 
were observed between paired experiments at. each nicotine 
concentration (see Fig. 4.8).
4.2.2 EFFECTS OF NCI ON [3H] NICOTINE BINDING TO TRITON
EXTRACTS OF P2 MEMBRANES
4.2.2.1 Equilibrium binding studies
Having selected assay conditions comprising of a
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final Triton X-100 concentration of less than 0.1%, and a 
protein concentration in the range of l-2mg/ml-in Krebs- 
HEPES-TRIS buffer, saturation binding studies were 
performed on detergent extracts to determine [3H]nicotine 
binding parameters. Data analysis was performed as shown in 
section 2.2.1.5. Briefly, the dissociation constant (Kd) 
and site density (Bmax) were first calculated by the method 
of Scatchard et al. (1949), these values were then used as 
"first estimates" for an iterative least-squares curve 
fitting of the binding data performed on SIGMAPLOT 4.1 
software package. Binding was found to be to a single class 
of sites, Kd = 16±2nM, Bmax = 104±12fmol/mg (mean ± SEM, 
n=13). Typical data are shown in Fig. 4.9.
The four antagonists were assayed for competition 
with [3H] nicotine using the radioligand close to its Kd 
(10nM). Saturation binding assays in the presence and 
absence of each of the antagonists were then performed. 
These experiments were to provide information about the 
antagonists' interactions with the labelled nAChR, by 
showing which of radioligand's binding parameters were 
affected in their presence.
4.2.2.1.1 Dihydro-S-erythroidine
DHSE was found to be an efficient inhibitor of 
[3H]nicotine binding (IC50 = 5.3±2.6/xM; see Fig.. 4.10). In 
the presence of 5/*M DHSE, the Kd was significantly reduced 
in comparison to control (control Kd = 18±3nM; with DHEE,
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Kd = 63±10nM, p>0.01; see Fig. 4.11) whereas there was no 
significant difference in the number of sites (control Bmax 
= 8 8 ±15 f mol/mg; with DHBE, Bmax = 113±llfmol/mg) . Such
observations would be predicted for a truly competitive 
antagonist (see section 5.2).
4.2.2.1.2 Mecamylamine
Mecamylamine did not compete strongly with [3H] - 
nicotine for agonist binding sites (IC50>lmM; see Fig. 
4.10), its effect appearing to be rather similar to that of 
chlorisondamine (see section 4.2.2.1.4). Saturation studies 
suggested the interaction of agonist, NCI and receptor to 
be more complex. Initial analyses revealed that at 180/zM, 
mecamylamine induced curvilinearity (concave downwards) in 
the Scatchard analyses of saturation binding, the data best 
fitting a second order regression (n=3; see Fig. 4.12A). 
This pattern was repeated at both lower (60/zM; n=2) , and 
higher (600fiM; n=2) , concentrations of mecamylamine (see 
Fig. 4.12B).
This curvilinear response suggests that at lower 
radioligand concentrations (up to approximately lOnM), 
nicotine binding was inhibited to a greater .extent by 
mecamylamine than at higher concentrations. Consequently, 
some characteristics of [3H]nicotine binding at a 
representative "low" concentration (2nM) of radioligand in 
the presence and absence of mecamylamine were investigated. 
Thus, [3H]nicotine binding in the presence of mecamylamine 
(180/iM) appeared to reach equilibrium much faster than in
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controls as measured by the time taken to reach half 
maximal levels of binding (t^ ) . Non-linear curve fitting 
indicated a six fold difference in the tu values . in the 
presence and absence of the antagonist (2.7 compared with 
18.8 minutes respectively, see Fig. 4.13). If the 
association rate is assumed to partially reflect the change 
from a predominantly R to D state within the receptor 
population, then the reductions of t are consistent with an 
increase in the rate of nAChR desensitisation in the 
presence of NCIs (see section 1.4.1).
Even though equilibrium was reached more quickly 
in the presence of NCI, the amount of [3H] nicotine bound 
under such conditions was lower than controls (2.5fmol/mg 
in the presence of mecamylamine compared with a control 
value of 5.2fmol/mg) . Competition assays, using [3H] nicotine 
at 2nM, instead of lOnM, showed mecamylamine to inhibit 
agonist binding more strongly at this lower radioligand 
concentration; the IC50 value calculated from these data 
being at least 2 orders of magnitude higher than earlier 
estimates (against lOnM nicotine, IC50>lmM; against 2nM, IC50 
= 89±37/-iM, see Fig 4.14J. From these data, one would
anticipate a 60-70% decrease from a control value.in the 
binding of 2nM [3H] nicotine in the presence of 180/zM 
mecamylamine. This compares favourably with saturation 
binding data in which a 66% reduction was noted at this 
radioligand concentration (control binding 11.4±1.4fmol/mg, 
with mecamylamine 3.7±1.7fmol/mg; n=3).
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4.2.2.1.3 MK-801
4 . 2.2.1.3AEffects on r3Hl nicotine binding to Triton X-100
extract
The presence of 50/zM MK-801 in saturation binding 
experiments had no effect on [3H] nicotine binding parameters 
(data not shown); this observation is wholly consistent 
with competition assay data in which the IC50 was found to 
be greater than ImM (see Fig. 4.10). However a qualitative 
difference between this and the other NCI was apparent. 
Whereas mecamylamine and chlorisondamine appeared to reduce 
[3H]nicotine binding gradually from lOfiM, MK-801 had no 
effect at concentrations up to approximately 100/iM; greater 
than this, inhibition was marked. The mechanism by which 
this reduction was achieved was investigated by measuring 
the effect of 500/xM MK-801 on [3H] nicotine binding
parameters (see Fig. 4.15). At this concentration of MK- 
801, the data hinted at an effect on [3H] nicotine affinity 
for solubilised nAChR, although this was not statistically 
significant (Kd = 29±8nM; control Kd = 13±2nM, n=3; p<0.1). 
No significant difference was observed between the number 
of sites in the presence o;r absence of MK-801 (with MK-801, 
Bmax = 105±39fmol/mg; control, Bmax = 83±32fmol/mg)..
In contrast to mecamylamine, the concentration of 
[3H]nicotine used in competition binding assays had no 
effect on the ability of MK-801 to inhibit radioligand 
binding; IC50>lmM at both 2nM and lOnM [3H] nicotine (see 
Figs. 4.10 and 4.14). However, the t^  of radioligand 
association in the presence of 500/zM MK-801 at 2nM [3H] -
112
nicotine was reduced (3.8 minutes compared with 18.8 
minutes in controls).
4 . 2 . 2 .1. 3BT3H1 MK-801 binding
In order to further characterise the relationship 
of the MK-801 and agonist binding sites, some preliminary- 
binding studies using [3H]MK-801 were performed, taking 
advantage of the defined and homogeneous nAChR expressed by 
the M10 cell line. [3H]MK-801 (final concentration 5/zM) was 
found to bind specifically to immunoimmobilised a4£2 
receptors (see Fig. 4.16). At this concentration, total 
[3H]MK-801 binding was between 55-6Ifmol/immunoimmobilised 
10cm diameter plate of cells; non-specific binding (as 
defined as that to an equvalent volume of Sepharose-GART) 
varied between 50-60% of the total. Comparison of the 
amounts of [3H] nicotine (20nM) and [3H] MK-801 (5/*M) bound to 
identical samples gave a stoichiometry in the region of 
4:1, respectively. [3H]MK-801 binding was found to be 
unaffected by the inclusion of 10/zM unlabelled (-) nicotine, 
but was displaced by 10/xM PCP, in contrast to [3H] nicotine 
binding.
4.2.2.1.4 Chlorisondamine
4.2.2.1.4AEffects on T3H1nicotine binding to Triton X-100
extract
In competition assays against [3H]nicotine, 
chlorisondamine was quantitatively similar to both 
mecamylamine and MK-801 (ICS0>lmM; see Fig. 4.10), though
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qualitatively its affect more closley resembled that of 
mecamylamine. Saturation binding assays in the presence o f - 
20/xM chlorisondamine led to a significantly lower 
estimation of Bmax than that in controls (79±9fmol/mg, 
compared with 145±16fmol/mg; n=3; p<0.02). The data also 
suggested a reduction in the affintiy of the receptor for 
[3H]nicotine in the presence of the antagonist, though the 
difference was not statistically significant (Kd = 30±llnM 
compared with 20±5nM in controls; p<0.1). Typical binding 
curves and Scatchard plots are shown in Fig. 4.17.
4 .2.2.1.4BEffects of in vivo administration of
chlorisondamine on T3H1nicotine binding 
One of the most interesting features of 
chlorisondamine action is the extended time period over 
which it appears to be effective as a central nicotinic 
antagonist (see section 4.1.4). To investigate this 
phenomenon, groups of six rats received subcutaneous 
injections of chlorisondamine, such that the final 
concentration was lOmg/kg (after Clarke, 1984) , or saline 
as controls (see section 2.2.3). A week after the 
injections, the animals were killed, and [3H]nicotine (40nM) 
binding to cortical and hippocampal membrane preparations 
was examined in both groups.
The binding data are summarised in table 4.1
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Table 4.1 Effects of in vivo chlorisondamine administration 
on [3H] nicotine binding to cortical and hippocampal membrane 
preparations (n=6).
Injection Cortex Hippocampus
Saline 82±4 fmol/mg 12±3 fmol/mg
Chlorisondamine 106±15 fmol/mg 15 ±2 f mol/mg
In the cortex, chlorisondamine treated animals 
showed a 25% increase in [3H]nicotine binding sited compared 
with controls, but this was not statistically significant 
(p>0 .1), reflecting the considerable variance in this 
group, as depicted in a scatter plot of the individual 
values (see Fig. 4.18) . Interestingly, the controls display 
considerably less variability. A lack of effect by 
chlorisondamine is supported by the data for hippocampus. 
These data suggest that whatever the mechanism by which 
chlorisondamine achieves its long term blockade, it does 
not appear to lead to a change in the number of [3H] - 
nicotine (thus a4£2 nAChRl binding sites in the cortex or 
hippocampus.
4.2.2.2 Kinetic binding studies
Kinetic studies were used to further investigate 
the unusual effects that mecamylamine was observed to have 
on [3H]nicotine binding, and particularly the dissocaition 
constant (see section 4.2.2.1.2). For a given ligand, the
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Kd can be defined as the ratio of dissociation rate (k x) 
and association rate (k+1) constants, thus:
Kd = k_x/k+1 --  (1)
Although k x can be directly measured in binding assays, k+l 
cannot. However, a related term, the pseudo - first order 
"observed" association rate (kobs) , may be derived 
experimentally. This, in combination with k , allows 
calculation of Kd, either with or without the use of 
equilibrium binding data (see section 4.2.2.2.3).
4.2.2.2.1 Association kinetics in rat brain detercrent
extracts
The time course of association was followed by 
measuring the amount of [3H] nicotine bound to detergent
extract as a function of time (see section 2 .2 .3.2).
Initial experiments were performed over a period of 3 
hours, and showed binding to be hyperbolic, with a t^  = 3.5 
minutes (see Fig 4.19). Subsequent analyses, both in
control and test cases, focussed on the initial, rapid 
binding phase; binding was assayed at intervals up to 30 
minutes and at 3 hours (taken as equilibrium). The reaction 
was found to have a mean koba = 0.084nM‘1min'1 (see Fig.
4.20A; SEM shown in Table 4.3). Whilst these data concur 
quantitatively with those of Lipiello & Fernandes (1986; kobs 
= 0 . OSnM^min"1) , it should be noted that the koba is only 
constant under fixed conditions and the similarity of
little consequence.
Interestingly, [3H]nicotine association to rat 
brain membranes was reported to be a biphasic function, 
rather than the hyperbolic one shown here. McCarthy & Moore
(1992) have shown that the lipid environment affects 
receptor conformation; thus, the process of receptor 
solublisation may be responsible for this subtle difference 
in mechanism.
4.2.2.2.2 Dissociation kinetics in rat brain detergent 
extracts
Given the similarity between the [3H] nicotine 
association kinetics observed in membrane-bound and 
solubilised nAChR (see section 4.2.2.2.1), it seemed likely 
that the first order dissociation reported by Lipiello & 
Fernandes (1986; k = 0.04min"1) would hold for detergent 
extracts. Thus, a full time course was not measured, 
rather, binding was assayed at equilibrium, then intervals 
up to 30 minutes after isotopic dilution of the radioligand 
with unlabelled nicotine (see section 2.2.3.2) . Under these 
conditions, k_x = 0.059min",1 (see Fig. 4.21A). This suggests 
that [3H]nicotine dissociation from solublised nAChR to be 
more rapid than that from membrane-bound receptors; the 
significance of this however is unclear.
4.2.2.2.3 Effects of NCI on association/dissociation 
kinetics
The presence of mecamylamine (180/zM) has already
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been shown to increase the observed association rate of 
[3H]nicotine binding to Triton extracts at a radioligand 
concentration of 2nM (see section 4.2.2.1.2). However, this 
effect was reversed when a [3H]nicotine concentration of 
lOnM was used; mecamylamine actually appeared to reduce the 
association rate under these conditions (koba = O.O6611M'1 
min'1, see Fig. 4.20B) . However, mecamylamine was not unique 
in its seemingly contradictory actions on [3H]nicotine
association. Thus, MK-SOl (500/HVI) was found to apparently 
increase the rate of radioligand association at 2nM 
[3H] nicotine (koba = 0.302nM'1min"1) , and decrease it at lOnM 
[3H] nicotine (k . = 0 . OSlnM^min'1) .ODS
Such deviations of the k . from controls areobs
reflected in the calculated tu values for [3H]nicotine
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binding to Triton extracts. Thus, whilst the effect of 
mecamylamine on 2nM radioligand association is quite 
pronounced (see Fig. 4.13), the presence of either 
antagonist has only a minor effect on the t^  of lOnM 
[3H] nicotine association (see Fig. 4.22) . All the tu values
7)
are summarised in Table 4.2
The increases in koba observed at low radioligand 
concentrations as a result of coincubation with the two 
antagonsits were found to be statistically significant 
(p<0.02). The reductions from control values at lOnM [3H]- 
nicotine, whilst routinely observed, were not statisically 
significant; this probably being due to the wide variations 
in the [3H] nicotine binding values seen between experiments.
Dissociation rates were too rapid to be resolved
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with any confidence at 2nM [3H] nicotine. However, the 
presence of either antagonist seemingly had little effect 
on radioligand dissociation at lOnM [3H]nicotine, with 
values closely resembling controls (with mecamylamine, k 
O.OSSmin'1; with MK-801, k_t = O.OSSmin'1). Data are 
illustrated in Figs. 4.21B and 4.21C.
Table 4.2 The half times for [3H] nicotine (2nM and lOnM) 
association in the presence and absence of NCI
[3H] Nicotine 
concentration
tu (minutes)
72 ........
Control ■ + 500^M 
MK-801
+ 180/xM 
me camylamine
lOnM 3.5 6.1 8.8
2nM 18.8 3.8 2.7
4.2.2.2.4 Calculation of Kd values from kinetic data
The association rate constant, k+1, cannot be 
directly measured in this type of assay. The amount of 
ligand bound at a given time depends simultaneously on 
association and dissociation mechanisms. These are related 
to k . such that:obs
k =b= =  K i -  [L] + k -x
[L] = ligand
concentration
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By rearranging these terms, k+1 is found to be
equal to:
Ki = <kob. - y / I L ]  —  (2)
Substituting equation (2) into equation (1) (see 
section 4.3.2) gives:
Kd = - k j  --- (3)
It is also possible to express k+1 in terms of 
formation of the receptor-ligand complex. The second order 
equation this approach yields may be simplified by assuming 
[L] is constant throughout; an assumption made acceptable 
by the great excess of ligand when compared with the actual 
number of specific binding sites available (nano- compared 
with picomolar).
From this.basis it can be shown that:
k+i = kobs. [Be) / [L] .Bmax ---- (4)
[Be] = concentration of 
ligand
bound at equilibrium 
Bmax = Number of binding 
sites
Substituting equation (4) into equation (1):
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Kd = k^. [L] .Bmax/koba.Be --  (5)
This provides two expressions ((3) and (5)) from 
which it is possible to derive Kd values; one independent 
of equilibrium data, the other requiring an estimation of 
the number of binding sites. Both were used here. The 
values calculated (control, and in the presence of MK-801 
or mecamylamine) , as well as the kinetic data from which 
they are calculated, are summarised in Table 4.3.
Drug k
009 V.
Calculated Kd (nM)
From (3) From (5)
Control 0.084 
± 0.024 
(n=6)
0.059 
± 0.003 
(n=6)
24 29
+ mecamylamine 
(180/xM)
0.066 
± 0.019 
(n=4)
0.056 
± 0.003 
(n=4)
56 29
+ MK-801 
(500/xM)
0.061 
± 0.019 
(n=4)
0.055 
± 0.004 
(n=4)
92 60
Table 4.3 On- and off-rates of [3H] nicotine binding to 
Triton extracts in the presence and absence of mecamylamine 
and MK-801, and the subsequent changes in radioligand 
affinity as calculated from those data.
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4.2.3 THE ACTION OF NCI ON tt4fi2 nAChR FUNCTION
The effects of the antagonists at functional c*4&2 
nAChR were investigated by means of a 8SRubidium+ influx 
assay using the M10 cell line (see section 2.2.2.5). Dose 
response curves were constructed by measuring the ion flux 
in response to IfiM (-) nicotine for one minute in the 
presence of increasing concentrations of each of the 
antagonists and comparing with the response seen in their 
absence. Dose-response curves for mecamylamine and MK-801 
are shown in Fig. 4.23. Curves for chlorisondamine blockade 
were incomplete over the range of antagonist concentrations 
used. However, there did not appear to be any agonist- 
induced 86Rubidium+ influx at chlorisondamine concentration 
greater than lxlO'8M. This suggests that chlorisondamine is 
an extremely potent antagonist. In addition, no curve was 
obtained for DH&E, experimental data proving to be highly 
variable. The only consistent feature was the failure of 
the antagonist to achieve complete blockade of the 
receptor-mediated influx, even at high (1/zM) 
concentrations. A possible explanation may stem from recent 
observations of Alkondon,& Albuquerque (1993). In their 
measurement of whole cell currents from hippocampal 
neuronal cultures, they noted that the interaction of DHBE 
with nAChR was slower than that with their agonist, ACh. 
Consequently, if the two were applied simultaneously, 
receptor activation proceeded too quickly to be inhibited 
by DHSE. The IC50 values are summarised in Table 4.4.
Table 4.4 Antagonism of agonist-induced B6Rubidium ion flux 
in M10 cells (N.D. = not determined)
Antagonist IC50 (M)
DHSE N.D.
Mecamylamine 1. OxlO'6 (n=3)
MK-801 l.lxlO'4 (n=3)
Chlorisondamine <1. OxlO"8 (n=2)
4.3 DISCUSSION
Non-competitive inhibitors (NCIs) may interact 
with three distinct categories of saturable binding sites 
on nAChR: a single, high affinity site, a population of 
lower affinity sites, and, at high concentrations, the two 
agonist binding sites (see section 1.4). The high affinity 
site is conventionally equated with the site labelled 
within the ion channel by CPZ and TPMP (see section
1.4.1.2); the low affinity sites are less well defined. 
NCIs are able to shift nAChR from the resting, R, state to 
a desensitised, D, state (see section 1.4). This may not be 
an identical structural conformation to that induced by 
extended exposure to agonists. The NCI has a higher 
affinity for the D state, and binds to the small proportion 
of nAChR always present in this state. The distribution of 
conformations within the receptor population is then
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pulled, essentially completely, towards the D state by mass 
action. This stabilisation of the D state by the antagonist 
may be achieved by interaction with either the high or low 
affinity binding sites.
4.3.1 Dihvdro-S-ervthroidine
DHEE has been reported to be a simple competitive 
antagonist (see section 4.1.4); the data presented here 
confirm this. In competition assays with [3H]nicotine, DHSE 
inhibited binding with a greater potency than the other 
antagonists (1C50 = 5.3/zM). This inhibition was due a
significant reduction in the affinity of [3H]nicotine 
binding to Triton extracts (see Fig.. 4.11), as would be 
expected for a competitive inhibitor. The affinity of DHJSE 
for the functional, R-state nAChR proved more difficult to 
measure. Previous studies suggested an affinity in the 
micromolar range (see section 4.1.4); a similarity in 
affinity for both R- and D-states is also characteristic of 
competitive antagonists (see section 5.1). However the 
antagonist appeared ineffectual in the 86Rubidium+ influx 
assay, even at high concentrations. This lack of efficacy 
may stem from a difference in the association kinetics of 
agonist and antagonist, as suggested by Alkondon & 
Albuquerque (1993); (-)nicotine was able to bind to, and 
activate, the receptor more quickly than DHSE could have 
its effect. This could be tested quite readily by examining 
the effect of preincubation of the Mio cells with DHSE upon 
ion flux.
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4.3.2 Mecamylamine
In contrast to the apparent confusion concerning' 
the mechanism of mecamylamine interaction with nAChR (see 
section 4.1.2), there is a surprising degree of consistency 
to the concentrations of mecamylamine reported to elicit 
functional receptor blockade. Thus, the IC50 value reported 
here for mecamylamine at M10 cell a4£2 nAChR (1/zM; see 
section 4.2.3) compares favourably with the inhibition of 
[3H]dopamine release from striatal synaptosomes (Rapier et 
al.,1990) . A 50% blockade of the putative a4£2 nAChR in the 
latter system was achieved at 5/zM mecamylamine. When 
expressed in Xenopus oocytes, lOOnM mecamylamine inhibited 
a4£2 nAChR-derived currents (Bertrand et al.,1990). 
Unfortunately, the percentage blockade at this 
concentration was not recorded. At ganglia, 25-lOOnM 
mecamylamine attenuated nicotinic responses (Ascher et al., 
1979), whilst Lukas (1989) reported an affinity of 0.2/zM in 
PC12 cells. The antagonist may be less potent at muscle- 
type nAChR; in TE671 cells IC50 = 30/zM (Lukas, 1989) , though 
IO^ iM was sufficient to completely depress evoked frog 
muscle twitches (Varanda et al., 1985).
Saturation [3H]nicotine binding studies in the 
presence of mecamylamine gave rise to curvilinear Scatchard 
transforms (see Fig. 4.12). The shape, concave downwards, 
is believed to be indicative of positive cooperativity (De 
Lean & Robard, 1979), though the underlying mechanism in 
such an instance is unclear. It is possible that the effect 
may be artifactual; reproducibility at various
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concentrations suggests this is not the case. Kermode
(1989) suggested several possible causes of such artifacts
in Scatchard analyses. However, all appear equally
applicable to assays both in the presence and absence of 
mecamylamine (which were conducted in parallel), or, are of 
no relevance to a detergent extract. Interestingly, 
Takayama et al. (1989) reported no curvilinearity when 
performing a similar assay in the presence of 600^M 
mecamylamine. It is possible that the use of membrane-bound 
nAChRs in this study prevented whatever underlies the 
observation; the lipid environment is known to effect
receptor conformation (McCarthy & Moore, 1992).
Nevertheless, the effect is peculiar to mecamylamine, and 
was not seen when the other antagonists were examined. One 
possible interpretation of the binding data is that under 
certain assay conditions, the receptor population is no 
longer solely in a single desensitised state, but two 
structurally distinct conformations. This concept is 
explored further in section 5.2.
4.3.3 MK-801
The effects of MK-801 on [3H]nicotine binding to 
Triton X-100 extracts, and what those data imply about the 
drug's mode of antagonism, are fully discussed in section 
5.2. The potency of MK-801 in attenuating 86Rubidium+ flux 
into M10 cells is less than might have been predicted from 
Ramoa et al. (1990) , in which 25/zM was reported as 
sufficient to inhibit (-)nicotine-evoked r-amino[2,3-
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3H]butyric acid release from hippocamapal synaptosomes.
The sensitivity of [3H]MK-801 binding to PCP 
confirms the identification of the antagonist as a channel 
blocker in neuronal nAChR. However, no increase in [3H]MK- 
801 was evident on addition of agonist. One possible 
explanation is that the binding of the receptor oligomer by 
the monoclonal antibody used in the purification procedure 
"locks" the nAChR into a more rigid, though still 
desensitised, state. It should be noted that Ramoa et al.
(1990) saw no increase in binding to muscle-type receptors, 
thus the effect of the antibody may be negligible. If MK- 
801 follows the pattern of PCP and Hl2-HTX (both of which it 
can displace; see section 4.1.2), and is, in allosteric 
terms, a "non-exclusive effector" (Rubin & Changeux, 1966), 
then its affinity for the channel blocker site is only 
marginally greater in the presence of an agonist than in 
its absence in any case.
4.3.4 Chlorisondamine
Chlorisondamine produces a long-lasting central 
nicotinic blockade, though its mechanism of action is 
poorly characterised (see section 4.1.4). The ion flux 
dose-response curve for chlorisondamine suggests it to be 
a highly potent antagonist of nAChR function, almost 
totally attenuating 86Rubidium+ when present in 
concentrations greater than 1x 10‘8M (see section 4.2.3). If 
a slow rate of metabolism is assumed for the drug, one 
might envisage a situation in which the chlorisondamine
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concentration in vivo remains in excess of that required 
for nAChR blockade for some considerable time.
Chronic in vivo exposure to (-) nicotine and other 
agonists leads to an increased density ("upregulation") of 
[3H]nicotine binding sites (reviewed in Wonnacott, 1990). It 
has been suggested that a prolonged, agonist-induced 
desensitisation underlies these observations, and 
consequently treatment with antagonists should yield 
similar results. In this study, there was no statistically 
significant increase in the mean [3H]nicotine binding 
density in chlorisondamine-treated animals, compared to 
controls. Binding data from the cortices of treated animals 
showed a particularly wide scatter (see Fig. 4.18); half of 
the subjects had greatly elevated levels of binding, whilst 
the other half were similar to controls. The concentration 
of chlorisondamine used was that reported to be effective 
by Clarke et al. (1984) , thus one must presume that the
drug crossed the blood-brain barrier. The relationship 
between treatment time and the rate of the mechanisms 
involved in any possible upregulation of nAChR is crucial. 
Thus, whilst all subjects received the same dose of 
chlorisondamine and all were killed one week later, the 
different levels of response to the drug treatment may be 
due to variability in the rate of chlorisondamine 
metabolism between individuals.
Chlorisondamine appeared to reduce [3H]nicotine 
binding to Triton extracts in competition assays from 
concentrations of lxlO"sM. This attenuation of binding
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seemed to stem from reductions in both the number and 
affinity of binding sites (see Fig. 4.17), though only the 
reduction in the former was statistically significant. 
These observations imply that chlorisondamine may act as 
both a competitive and allosteric inhibitor. Interestingly, 
Daly et al. (1991) reported that, in PC12 cells at least, 
the affinities of chlorisondamine for the agonist and 
channel blocker binding sites were very similar. The
mechanism of action is obviously a complex one; for further 
discussion, see section 5.2.
4.3.5 Summary
The interactions of a number of antagonists with 
the neuronal a4£2 nAChR subtype have been examined. Whilst 
all were able to attenuate 86Rubidium+ influx, each of the 
four antagonists - DHSE, mecamylamine, MK-801 and
chlorisondamine - had different effects on high affinity 
agonsit binding to Triton X-100 extracts of rat brain P2 
membrane preparations. The possible mechanisms behind these 
observations are examined in sections 5.1 and 5.2.
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Fig. 4.1 Energy minimised structural models of (A) DH&E, 
(B) mecamylamine, (C) MK-801 and (D) chlorisondamine.
Structures were provided courtesy of P. Thomas, and were 
built using the HYPERCHEM modelling package (Autodesk Inc., 
California, U.S.A.). Individual atoms are represented as 
colour coded van der Waals spheres (white - oxygen,- pale 
blue - carbon; dark blue - nitrogen; red - oxygen; green - 
chlorine).
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Fig. 4.2 Comparison of non-specific [3H]nicotine binding to 
Triton extracts in different buffering systems. P2
membranes were extracted with 0.5% (v/v) Triton X-100 in a 
series of different buffers (50mM Phosphate, Krebs-HEPES, 
and Krebs-HEPES additionally containing 200mM TRIS) . [3H] -
Nicotine binding (final concentration 20nM) was assayed by 
standard techniques (see section 2.2.1.3.1) . In each assay, 
non-specific binding, measured in the presence of 
unlabelled nicotine, was calculated as a percentage of the 
total in each buffer. Each column represents the mean±SEM 
of three separate determinations. For comparison, each set 
of data was then standardised against the non-specific 
[3H]nicotine binding in the phosphate buffer (which was 
taken as 100%). * Significantly different from phosphate
buffer (p<0.05).
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Fig. 4.3 Comparison of the properties of different glass- 
fibre filter grades with respect to (A) specific and (B) 
non-specific [3H]nicotine binding to Triton extracts.
[3H] Nicotine binding (final concentration 20nM) to identical 
detergent extract samples in Krebs-HEPES-TRIS buffer was 
assayed as previously. Bound and free radioligand were 
separated from unbound by filtration on GFA/E, GFB and GFC 
glass-fibre filters. Bound radioactivity was calculated as 
fmol [3H]nicotine/mg protein (open columns) or % total 
binding (shaded columns). Each column represents the meann 
SEM of three separate determinations.
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Fig. 4.4 The effects of Triton X-100 on [3H] nicotine 
binding (I) . (A) [3H] Nicotine binding (20nM) to Triton X-100 
extract (supernatant) and residual pellet expressed as a 
percentage of the original P2. (B) Effect of increasing
Triton X-100 concentration on [3H]nicotine binding to P2 
membranes.
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Fig. 4.5 The effects of Triton X-100 on [3H] nicotine 
binding (II). [3H]Nicotine binding (20nM) to detergent 
extracts was assayed at a constant protein concentration in 
the presence of increasing concentrations of Triton X-100. 
Each point is the mean ± SEM of 3 determinations.
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Fig. 4.6 Comparison of [3H] nicotine binding to P2 membranes 
and Triton extracts. Scatchard analyses of [3H]nicotine 
saturation assays performed in parallel on a P2 membrane 
preparation (•), and a Triton extract prepared from it (O) 
are shown. The data are from a single representative 
experiment performed as previously, using triplicate 
samples. The binding parameters were calculated as: Kd: P2 
= llnM, extract = 9nM; Bmax: P2 = 62fmol/mg, extract = 43fmol/mg.
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Fig. 4.7 The effect of Triton X-100 on protein 
determinations. Concentrations of BSA standards were 
determined by the Lowry method (Lowry e_t al. , 1954) in the 
absence ( O )  and presence (•) of lOpil Krebs-TRIS -HEPES 
buffer additionally containing 0.5% (v/v) Triton X-100. The 
data shown are from a single representative experiment, 
each point representing the mean of triplicate samples.
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Fig. 4.8 The effect of ethanol on [3H] nicotine binding.
[3H]Nicotine binding to Triton extracts was assayed at three 
radioligand concentrations (InM, 15nM and 40nM) in the 
presence (shaded columns) and absence (open columns) of 
l O f i l 95% (v/v) ethanol. Each column represents the mean ± 
SEM of three determinations.
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Fig. 4.9 Typical [3H]nicotine binding parameters in Triton 
X-100 extracts. [3H]Nicotine saturation binding to Triton 
extracts typically gave hyperbolic specific binding curves. 
Specific [3H]nicotine binding was calculated as the 
difference between radioligand binding to Triton extracts 
assayed in the absence (TOTAL BINDING) and presence (NON­
SPECIFIC BINDING) of excess (1/zM) unlabelled (-) nicotine 
(see section 2.2.1.3.1). Representative data (A) and 
Scatchard transformation (B) from a single experiment are 
shown. In this experiment Kd = llnM, Bmax = 135fmol/mg 
(regression coefficient = -0.98).
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Fig. 4.10 The effects of DH£E, mecamylamine, MK-801 and 
chlorisondamine on [3H]nicotine binding to Triton X-100 
extracts. Specific [3H] nicotine binding (triplicate samples, 
final concentration lOnM) to Triton extracts was assayed in 
the presence of increasing concentrations of each of the 
four antagonists. The data were expressed as a percentage 
of the binding observed in the absence of the drugs. Each 
point represents the mean ± SEM of three separate 
determinations.
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Fig. 4.11 The effect of DHBE on [3H] nicotine binding 
parameters in Triton X-100 extracts. Saturation binding of 
[3H]nicotine to Triton extracts was measured in the presence 
(•) and absence (O) of 5/zM DHSE. A representative specific 
binding curve (A), and Scatchard transformation of the data 
(B) , are shown. In this experiment control, Kd = 20nM and 
Bmax = 92 fmol/mg; in the presence of DHSE, Kd = 48nM and 
Bmax = 94fmol/mg.
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Fig. 4.12 The effect of mecamylamine on [3H] nicotine 
binding parameters in Triton X-100 extracts. (A)
Representative experiment of saturation binding to Triton 
extracts was measured in the presence (a ) and absence (O) 
of 180/iM mecamylamine. Representative Scatchard 
transformations of the data are shown. In this experiment, 
control Kd = 15nM, Bmax = 88fmol/mg. Scatchard data in the 
presence of mecamylamine best fitted a second order 
regression (r = 0.89); Kd was not determinable, Bmax was 
estimated at 86fmol/mg. (B) Scatchard analyses of another 
experiment of [3H] nicotine binding in the presence of 600/zM 
(0) and 60fiM (♦) mecamylamine. (Control Kd=16nM, 
Bmax=143fol/mg; data not shown.)
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Fig. 4.13 The time course of 2nM [3H]nicotine binding in 
the absence (A) and presence (B) of mecamylamine. The
association of 2nM [3H]nicotine with Triton extracts as a 
function of time was examined by determination of the 
amount of radioligand bound at intervals up to 180 minutes 
(which was taken as equilibrium) . In controls (A) , the time 
at which half-maximal saturation occurred (tK) was found, by 
a non-linear iterative curve fitting, to be 32 minutes. 
Each point represents the mean ± SEM of at least 4 
determinations performed in duplicate. In the presence of 
180/xM mecamylamine (B) , a similar analysis gave a t^  = 2.7 
minutes. Each point represents the mean ± the range of at 
least 2 determinations.
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Fig. 4.14 The effects of mecamylamine and MK-801 on [3H] - 
nicotine binding to Triton extracts at low radioligand
concentrations. Competition binding assays were performed 
as before (see Fig. 4.10), except that the [3H] nicotine
concentration was reduced from lOnM to 2nM. For
mecamylamine (180ptM; a ) , each point represents the mean ± 
SEM of 3 separate determinations, for MK-801 (500/xM; □) ,
each point represents the mean ± the range of 2
determinations.
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Fig. 4.15 The effect of MK-801 on [3H]nicotine binding 
parameters in Triton X-100 extracts. Saturation binding of 
[3H]nicotine to Triton extracts was measured in the presence 
(□) and absence (O) of 500/xM MK-801. Representative
specific binding curves (A) and Scatchard transformations 
of the data (B) are shown. In this experiment, Kd and Bmax 
values were: control Kd = 20nM, Bmax = 81fmol/mg; with MK- 
801 Kd = 53nM, Bmax = 99fmol/mg.
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Fig. 4.16 Comparison of [3H] nicotine and [3H]MK-801 binding 
to immunoimmobilised a462 nAChR. Three days after induction 
by 1/zM dexamethasone, a4£2 nAChR were solublised from M10 
cells, and [3H] nicotine (20nM) and [3H]MK-801 (5/xM) binding 
to the immunoimmobilised receptors was determined. Non­
specific radioligand binding was defined as that to an 
equivalent volume (25^ il) of Sepharose-GART. Control values 
of radioligand binding were: 99-103fmol and 55-61fmol/l0cm 
diameter dish for [3H] nicotine and [3H]MK-801 binding 
respectively.
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Fig. 4.17 The effect of chlorisondamine on the [3H]nicotine 
binding to Triton extracts. Saturation binding of 
[3H] nicotine to Triton extracts was measured in the presence 
(v) and absence (O) of 20/iM chlorisondamine. Representative 
specific binding curve (A) and Scatchard transformations of 
the data (B) are shown. In this experiment Kd and Bmax 
values were: control Kd = 19nM, Bmax = 115fmol/mg; with 
chlorisondamine Kd = 25nM, Bmax = 73 fmol/mg.
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Fig. 4.18 The effect of in vivo administration of 
chlorisondamine on [3H]nicotine binding to rat cortical and 
hippocampal membrane preparations. Two groups of six rats 
were treated with either chlorisondamine (10mg/kg; shaded 
columns) or saline (controls; open columns). After one week 
the animals were killed, and cortical and hippocampal 
membrane preparations were prepared from each individual 
brain. These were assayed for [3H]nicotine (40nM) binding. 
The columns represent the mean specific binding (n=6); the 
scatter plots show the individual data points.
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Fig. 4.19 The time course of lOnM [3H] nicotine binding to 
Triton extracts. The protocol and subsequent data analysis 
are as described previously (see Fig. 4.13). Each data 
point is the mean ± SEM of between 6 and 12 individual 
determinations performed in duplicate. The calculated t was 
found to be 3.2 minutes.
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Fig. 4.20 The observed association rates (k^) of lOnM [3H]- 
nicotine binding to Triton extracts in the absence (A) and 
presence of mecamylamine (B) and MK-801 (C) . To measure the 
initial, rapid phase of radioligand association, 
[3H]nicotine binding (final concentration lOnM) was assayed 
at intervals up to 30 minutes (see Fig. 4.19) and 180 
minutes. Each data point represents the mean ± SEM of 6 (A) 
or 4 (B,C) separate determinations, each performed in
duplicate. B and Be are the amounts of radioligand bound 
(in fmol/mg) at time T and equilibrium (180 minutes) 
respectively. The observed association rate (kob8) was 
measured from the gradient of the plot ln(Be/Be-B) against 
T (Lipiello & Fernandes, 1986) . Mean koba values were: 
control, 0.084nM"1min'1; with 180^M mecamylamine, 0.061 
nM^min"1; with 500/xM MK-801, 0 . OeenM^min'1.
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Fig. 4.21 The dissociation rates (k^) of lOnM [3H]nicotine 
from Triton extracts in the absence (A) and presence of 
mecamylamine (B) and MK-801 (C) . Triton extracts were
equilibrated with lOnM [3H] nicotine, and the binding 
assayed, an excess of unlabelled (-)nicotine was then 
added, and the radioligand remaining bound at intervals up 
to 30 minutes measured. B0 and B are the amounts of 
[3H]nicotine bound (in fmol/mg) after equilibration, and at 
time T after addition of unlabelled ligand respectively. 
The dissociation rate (k^) was determined from the gradient 
of the plot ln(B/Boxl00) against T (Lipiello & Fernandes, 
1986). Mean k_x values: control, 0.059min_1; with 180/zM
mecamylamine, O.OSSmin'1; with 500/xM MK-801, 0.055min_1.
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Fig 4.22 The time course of lOnM [3H]nicotine binding to 
Triton extracts in the presence of (A) mecamylamine and (B) 
MK-801. The binding data (mean ± SEM, n=4 for each drug) 
is that shown previously (see Fig. 4.20) curve fitted as 
for the control data (see Fig. 4.19). The half times of 
[3H]nicotine association were calculated to be 8.8 and 6.1 
minutes in the presence of 180/xM mecamylamine and 500/iM MK- 
801 respectively.
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Fig 4.23 The effects of mecamylamine, MK-801 and 
chlorisondamine on nicotine-mediated 86Rubidium ion flux 
into M10 cells. 86Rubidium influx in response to 1/aM (-)- 
nicotine was measured in the presence of increasing 
concentrations of mecamylamine ( a );MK-801 (□) or
chlorisondamine (v) . Data were expressed as a percentage of 
agonist-induced flux in the absence of either antagonist. 
Each point represents the mean ± SEM.
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5 DISCUSSION
The basic theme underlying nAChR function is one of 
allosteric modulation of receptor conformation. This is 
achieved by a wide range of "effectors", a diverse group of 
relatively small ligands which promote structural 
rearrangement within the receptor upon binding. The 
interaction of receptor and effector is thus reliant upon 
accurate ligand recognition, and the coupling of binding to 
effect (in what might be termed "signal transduction"). 
Within this context, the structures of both the effector 
and the receptor are obviously of great importance. For 
example, all agonists are of similar size, and conform to 
a model pharmacophore (see section 5.1). Similarly, whilst 
homologous, the multiplicity of nAChR receptor subunits has 
a profound effect on agonist interaction. Thus, subtle 
structural changes alter binding affinities, leading to 
distinctive pharmacological profiles for each receptor 
subtype. For antagonists, a choice of ligand binding sites, 
and subsequent effector mechanisms, adds further complexity 
(see section 5.2).
In this section, it is the author's intention to 
briefly examine the interaction of the two main effector 
groups - the agonists and antagonists - with nAChR in the 
terms of this dual mechanism of ligand recognition and 
signal transduction. Particular reference will be made to 
those drugs used in this study, and the possible molecular 
bases of their actions.
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5.1 Ligand recognition and receptor activation
All agonists contain a positively charged centre - 
the POSITIVE POLE - usually a quaternary ammonium salt, 
and, separated from it by 4.5-5.5A, a 7r-electron system 
which forms a local dipole capable of accepting a hydrogen 
bond (Cockcroft et al., 1990) . Competive antagonists, such 
as DHSE, are assumed to mimic this arrangement, and thus 
interfere with agonist binding. In turn, this pharmacophore 
defines the most important elements of the agonist binding 
pocket. Thus, a negatively charged subsite was considered 
an essential complement to the positive pole. Indeed, one 
of the persuasive features of the cys-loop (see section
1.2.1) as an agonist binding motif was thought to be the 
presence of an aspartate residue, one of only two invariant 
acidic amino acids present in the N-terminal domain of the 
a-subunit (Cockcroft et al., 1990). However, in affinity 
labelling studies, only aromatic residues in the region of 
the characteristic cysteines were highlighted (see Sequence
1.1). Whilst such residues could bind the positive pole 
(Dougherty & Stauffer, 1990), Czajkowski & Karlin (1991) 
have identified a 60 resi'due segment immediately prior to 
the Ml region of the 6-subunit as containing the negative 
subsite. Subsequent mutation studies showed that at least 
two of the ten acidic residues in this region (aspartate 
180 and glutamate 189) had a significant effect on ACh 
affinity (Czajkowski et al., 1992). Based on these data, 
Karlin (1993) has proposed that agonists bridge the binding 
pocket, extending from the negative subsite to the region
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around the disulphide. It is envisaged that ligand binding 
promotes a decrease in the distance between these two 
points, in effect moving one subunit relative to the other 
leading to channel opening. The elegance of this model 
extends beyond the linkage of ligand recognition and 
receptor activation however. The closure of the binding 
cleft around the agonist, a mechanism reminiscent of the 
"induced fit" of enzymes, may also be the basis of the 
increase in agonist affinity observed with the shift of the 
receptor from the R- to D-states (see section 1.3). Such 
closure would have the twin effects of optimising the 
interactions between agonist and receptor, and reducing 
access to the binding pocket; both would tend to increase 
apparent affinity for agonist. The existence of at least 
two non-functional conformations (the I- and D-states; see 
section 1.3.1) suggests that the necessary process of 
peptide rearrangement is not a smooth one; one might 
envisage local increases in free energy as neighbouring 
peptide chains move gradually into closer apposition 
suddenly relieved by a "flip" into a different 
conformation.
The kinetics of the ligand-receptor interaction may 
be influenced by the structure of the agonist; Papke et al.
(1988) reported differences in single channel kinetics when 
subtle changes were made in the steric and ionic character 
of the acetyl portion of ACh, for example. The distinctive 
nature of (+)AnTX-induced receptor activation and 
desensitisation may be a similar phenomenon. The usual
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increase in agonist affinity observed in the shift from R- 
to D-state was limited at transfected M10 cell a4£2 nAChR; 
the EC50/IC50 ratio for ( + )AnTX was approximately 20, 
compared to 350 for (-)nicotine. In addition, the dose- 
response curves appeared to be steeper than those of other 
agonists. Similar observations have been made in other 
systems. Thus, the curves for ( + ) AnTX-induced [3H]ACh 
release from rat hippocampal synaptosomes were steeper than 
those for (-) nicotine in the same system (Thomas et al., 
1992) . Using the Ki value for ( + )AnTX inhibition of 
[3H]nicotine binding to rat brain membranes from Wonnacott 
et al. (1991), the ratio of agonist affinities, 
approximately 30, was found to be in good agreement with 
that from the M10 cell line. Interestingly, an equally 
small shift is evident when the EC50 value of a-BgTX- 
sensitive currents in cultured hippocampal neurons (3.9/zM; 
Thomas et al., 1992) is compared with the ability of 
( + )AnTX to displace [125I] -aBgTX binding to rat brain 
membranes (0.38^M; Wonnacott et al., 1991). Data from al 
nAChR expressed in Xenopus oocytes were comparable to those 
from the cultures. In addition, the (+)AnTX dose response 
curves were notably steeper than the otherwise comparable 
(-)nicotine-induced activation curves in this system. The 
qualitative similarity of the responses of a4&2 and al 
nAChR to (+)AnTX is particularly striking, despite the 
large difference in agonist potency between the two 
receptor subtypes. Relating this back to the model, ( + )AnTX 
may better "fit" the gap between the disulphide and
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negative subsites than do other agonists when the receptor 
is in the R-state. One would predict that the close 
proximity of ligand and binding subsites would enhance the 
attraction between the two, and thus lead to a more rapid 
initial contraction of the agonist binding site. This has 
the effect of making the agonist more readily able to 
activate the receptor, giving rise to the steep dose- 
response curves. Such a theory might also imply that 
further contraction of the agonist binding site would be 
rather limited - due to steric interference by the agonist 
- hence the low EC50/IC50 ratios. It is likely that the 
distance between the two subsites is similar in all nAChR 
subtypes (they all have the same endogenous agonist), but 
that the surrounding molecular architecture differs 
considerably. This would explain the large difference in 
absolute affinities between the o?4fi2 and oil nAChR subtypes, 
and is itself simply a reflection of the sequence variation 
between the extracelluar domains of the different subunits. 
It would be interesting to see if these features of the 
(+)AnTX/nAChR interaction were repeated in other subtypes. 
However, it may require a different approach to that used 
here. Whilst the initial receptor activation phase is 
readily accessible to study in all subtypes by use of 
oocyte expression studies, the shift in affinity during the 
conversion from R- to D-state may prove more difficult to 
measure. The desensitised state of the o'4£2 and oil nAChR 
subtypes may be directly probed by high affinity ligand 
binding assays, this is not possible for the other
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subtypes. However, a method similar to that employed by 
Kemp & Morley (1986) might be used; the affinity of the 
desensitised receptor was calculated from the reduction in 
conduction observed.
The effect of receptor structure upon the interaction 
of an agonist and receptor cannot be over emphasised. The 
difference in subunit composition can, as alluded to above, 
radically alter the affinity for a given agonist. Thus, if 
the agonist binding site is formed from both a. and (in 
neuronal nAChR) £ subunits, changes in either one might be 
expected to have an effect. There is some evidence that 
changes in subunit composition affect other aspects of the 
agonist/receptor interaction. Thus, expression studies in 
Xenopus oocytes have suggested that neuronal nAChRs 
containing £2 and £4 subunits each respond differently to 
cytisine application; cytisine appeared to be only a 
partial agonist at £2-containing subunits (Leutje & 
Patrick, 1991; see section 3.3.1.2) . Chimeric subunits have 
recently been used to demonstrate the particular importance 
of the N-terminal domain in this respect (Figl et al., 
1992; Papke et al., 1993). The relative efficacy of 
cytisine in producing functional responses in the ion flux 
assay used in this study to measure a4£2 nAChR was thus 
somewhat surprising (see section 3.3.3).
It is possible that this difference in cytisine's 
efficacy is a species dependent phenomenon, the expression 
studies utilising rat- rather than chick-derived receptor 
subunits. A Xenopus oocyte-expressed avian a4£2 nAChR has
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indeed been recently shown to respond to cytisine as a full 
agonist, with an affinity very similar to that seen in the 
M10 cells (Wilkie et al., submitted). However, the same 
study reported analogous data from rat hippocampal 
synaptosomes, which suggests a more complicated reason than 
a simple species difference. Comparison of rat and chick £2 
N-terminal domain sequences suggests little basis for such 
a theory in any case. There are only six amino acid
differences between rat and chick sequences; four of these 
are conservative. The two residues which Figl et al. (1992) 
suggested were particularly important for relative 
insensitivity of rat £2-containing receptors to cytisine 
(in the mature protein, phenylalanine 108 and serine 110; 
see Sequence 5.1), are identical in chick £2. Papke et al. 
(1993) were less specific, merely noting that exchange of 
the first residues between £2 and £4 was sufficient to
alter cytisine sensitivity. Interestingly the two non­
conservative substitutions between rat and chick £2 occur 
in this first half of the N-terminal domain (positions 12 
and 30; see Sequence 5.1). Examination of the homologous 
positions in the rat £4 sequence adds a further dimension. 
Perhaps purely by circumstance, the residue at position 30
is identical to that in chick £2 (glutamine instead of
glutamate as in rat £2). In addition, at position 12, the 
histidine residue of £2 is replaced with glutamate; both 
this residue and the tyrosine in this position in chick £2, 
could act as hydrogen bond acceptors. Point mutation and 
oocyte expression could be used to assess the importance of
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these residues. They are unlikely to be involved in the 
negative subsite (acidic residues homologous to those 
identified by Czajkowski et al. (1992) being present in the 
region immediately prior to the Ml segment of chick £2 for 
example), though may be important in subsequent 
conformational shifts. Thus, whilst there is some basis for 
a similarity between chick £2 and rat £4, it may not be 
sufficient to explain the other contradictions in the 
literature.
Competitive antagonists, such as DH£E, also interact 
with nAChRs via the agonist binding site. As they are 
usually larger than the agonists (for example DH£E has a 
molecular mass of 275, compared with 145 to 190 for the 
four agonists used in this study) , it is possible that 
whilst spanning the binding pocket, they prevent subsequent 
structural rearrangements implicit in the model of receptor 
activation by Karlin (1993). In favour of this hypothesis 
is the similarity of the antagonist's affinity for the R- 
and D-states (see section 4.1.1). A greater bulk, and 
possible difficulties in achieving the correct orientation 
for recognition by the receptor, are probably the reasons 
behind the failure to observe a blockade of agonist-induced 
86Rb+ influx by DH£E (see section 4.2.3). The binding of 
competitive antagonists is capable of eliciting a 
conformational change however, and is probably a pre­
requisite of their action. Mutation and expression of al 
nAChR suggested that DH£E binding lead to channel blockade 
by the leucine ring of the M2 region (Bertrand et al.,
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1992; see section 1.3.2). This may only represent an 
intermediate step however (an analogue of the agonist- 
induced I-state perhaps) ; even with the removal of the 
leucine ring, currents still desensitised. A two-step 
inactivation was also suggested by McCarthy & Stroud
(1989), though through a somewhat different approach. Using 
hydrogen exchange as a measure of conformational change, 
they examined the effects of a number of effectors - 
agonists, competitive and non-competitive antagonists - on 
muscle-type nAChR. The largest change was induced by the 
competitive antagonist, ce-BgTX.
5.2 Modes of antagonism
Agonist-induced receptor activation depends upon the 
accurate recognition of the ligand, and the coupling of 
binding to channel opening; both elements may be disrupted 
by antagonists. Competitive inhibitors prevent ligand 
binding by mimicking the agonist, and occupying its site 
(see section 5.1). Non-competitive inhibitors may allow 
agonist binding, but prevent subsequent changes in 
conformation (an "allosteric inhibitor"), or leave both 
phases of activation undisturbed and sterically block the 
ion channel. Interestingly, Heidmann et al. (1983) defined 
three categories of saturable binding sites in their model 
of NCI interaction with muscle-type nAChR (see section
1.4.1). The implicit site specificity of two of the modes 
of antagonism - competitive inhibition and channel blockade 
- suggests a simple correlation between effector binding
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site and mechanism. By extending Heidmann's model, a 
general description of antagonist action at nAChR may be 
formulated. Basically, the mode of antagonism of any drug 
depends upon the relative affinity it displays for the 
three groups of binding sites. Thus, a competitive 
antagonist will favour the agonist binding site. In theory, 
as the concentration of the antagonist increases, a 
sequential occupation of progressively lower affinity site 
occurs; several mechanisms may thus occur simultaneously at 
high ligand concentrations. The model provides a useful 
frame- work within which to describe antagonist action at 
nAChR, acknowledging the importance of both ligand and 
receptor structure (which of course define binding 
affinity) on the mechanism of inhibition. However, it is 
insufficiently detailed to define the exact molecular basis 
of action, reflecting the poorly characterised nature of 
the binding sites. This is especially true of those 
Heidmann et. al. (1983) described as "low affinity sites", 
a blanket term covering all those not in either the agonist 
pocket of the ion channel. Thus the mechanisms below must 
be regarded as speculative.
Chlorisodamine significantly (p<0.02) reduced the 
number of [3H]nicotine binding sites as measured by 
saturation binding, with the data hinting at an additional 
effect on radioligand affinity (see section 4.2.2.1.4). 
When considering the effect of NCIs on high affinity ligand 
binding, the inevitable agonist-induced change in receptor 
conformation (see section 5.1) must also be addressed. In
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the absence of the agonist, it has been estimated that only- 
some 40% of the receptor population are in the correct 
conformation to bind [3H]nicotine with nanomolar affinity 
(Lippiello et al., 1987). The rate of conversion between 
conformations is dependent upon temperature and agonist 
concentration. Under the assay conditions utilised (see 
section 2.2.1.3), the receptor population within the Triton 
X-100 extracts may be regarded as entirely in the high 
affinity state. A clear analogy with enzyme/substrate 
interactions exists. Furthermore, the well characterised 
mechanisms of enzyme inhibition provide a useful basis for 
interpretation of the binding data presented here. So, for 
an enzyme following Michaelis-Menten kinetics, enzyme rate 
(v) increases as a hyperbolic function of substrate 
concentration ( [S] ) to a theoretical maximum (Vmax) . The 
[S] required to attain half maximal rate is given by the 
Michaelis constant (Km) . In the simplest case, Km is 
assumed to equal the dissociation constant of the 
enzyme/substrate complex. If one substitutes "binding 
sites" for "rate", and "ligand" for "substrate", then these 
parameters are analogous to those in a binding assay: Vmax 
becomes Bmax, whilst Km is equivalent to Kd. Several 
patterns of enzyme inhibition have been described. For 
example, a COMPETITIVE inhibitor increases the Km in 
proportion to the concentration and affinity (Ki) of that 
inhibitor; Vmax remains the same. Thus, DHBE likewise 
reduced the affinity (Kd) of [3H] nicotine binding, but had 
no effect on Bmax (see section 4.2.2.1.1). This suggests
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that the enzyme analogy is a valid one. To continue, an 
inhibitor which alters only the Vmax is said to be NON­
COMPETITIVE. If both Km and Vmax are changed, the mechanism 
may be one of either MIXED or UNCOMPETITIVE inhibition. The 
latter is particularly interesting in the context of
binding to nAChR, as the inhibitor only binds to the 
enzyme/substrate complex. Analogy with the classic
description of open channel blockade is obvious. Returning 
to chlorisondamine, a combination of the binding data and 
its action as reported in the literature (see section 
4.1.4) implies an "uncompetitive" action. However, there 
are certain difficulties associated with this 
interpretation. For instance, if both chlorisondamine and
MK-801 are open channel blockers, why do they have
different effects on [3H]nicotine binding? On a more 
theoretical basis, can binding within the ion channel cause 
a conformational change in the receptor as well as steric 
blockade? Whilst the inclusion of an agonist has been 
widely reported to enhance channel blocker binding in 
studies using muscle-type receptors (see Heidmann et al., 
1983, for example), there is little evidence that NCIs 
inhibit radioligand binding at anything other than very 
high concentrations. Thus, whilst the data in this study 
hinted at an effect by MK-801 on [3H]nicotine binding 
affinity (see section 4.2.2.1.3A), the model of antagonist 
action discussed previously would predict direct action at 
the agonist site. Certainly, lower MK-801 concentrations 
had no effect on agonist binding, nor did PCP at
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concentrations sufficient to abolish [3H]MK-801 binding to 
immunoimmobilised a4£2 nAChR (see section 4.2.2.1.3B). 
These data imply that little, if any, change in 
conformation accompanies channel blockade. It thus seems 
likely that the observed effects on high affinity agonist 
binding are mediated through interaction with a different 
site.
Lingle & Neely (1986) reported a second component, in 
addition to channel blockade, in the chlorisondamine 
inhibition of frog muscle nAChR (see section 4.1.4) . Full 
recovery of agonist-induced currents after incubation with 
the antagonist was not observed, despite protocol changes. 
This suggests that chlorisondamine was able to induce or 
stabilise a conformation in a part of the receptor 
population which was inactivatable, perhaps permanently. 
The reduction in the number of binding sites may be 
interpreted in a similar way; chlorisondamine induces or 
stabilises a conformation in which the receptor is unable 
to bind [3H] nicotine with high affinity. It is possible that 
the two observations are facets of the same phenomenon, and 
that the chlorisondamine-induced conformation is the same 
in both assay systems. The form this conformation takes, 
and the site at which the antagonist must bind to induce 
it, are unknown. However, the potency of chlorisondamine in 
attenuating 86Rb+ flux (IC50<lxlO'8M; see section 4.2.3) 
suggests that whatever the mode of antagonism, the binding 
affinity of the antagonist is unusually high.
Whilst analogy with enzyme studies provided at least
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an indication of the mechanism of chlorisondamine's 
interaction with nAChR, the same is not true of 
mecamylamine. The IC50 value for the mecamylamine-induced 
attenuation of 86Rb+ flux into M10 cells appeared to be in 
good agreement with those in the literature (see section
4.1.2) , However, the effect of mecamylamine on [3H] nicotine 
to Triton X-100 extracts was found to be quite distinctive, 
bearing little resemblance to the four patterns outlined 
previously. To summarise, the curvilinearity observed in 
the Scatchard transformations of saturation data from 
assays performed in the presence of mecamylamine, appeared 
to be due to a more profound inhibition of [3H] nicotine 
binding at the lower radioligand concentrations. This was 
reflected by a large decrease in the IC50 value for 
mecamylamine when determined at a representative low (2nM) 
[3H] nicotine concentration. Paradoxically, [3H] nicotine 
binding at this concentration, though reduced in comparison 
to controls, reached equilibrium more quickly. It was 
concluded that the binding data were indicative of receptor 
population displaying two comformational states, both 
inactive, though each with different ligand binding 
properties. Mecamylamine is an oddity amongst NCIs, 
examination of the literature suggesting that it displays 
different modes of antagonism at different receptor 
subtypes (see section 4.1.2). This is not inconsistent with 
the model presented earlier however. Differences in subunit 
composition undoubtedly generate subtle variations in the 
molecular architecture of a receptor; these could be
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sufficient to affect the affinity of one or more of the 
antagonist binding sites. Thus, it is possible to envisage 
a reordering of the sequence of site occupation - thus 
mechanism of inhibition - in different nAChRs. the question 
here is: what is the site and mechanism of mecamylamine!s 
interaction with the o?4S2 subtype?
Of the two conformations, one is undoubtedly the 
agonist-induced D-state. The other is unclear, but 
certainly displays a lower affinity for [3H]nicotine than 
the D-state. Comparable binding conditions (2nM 
[3H] nicotine, 180/xM mecamylamine) lead to a consistent 
proportion of the receptor population (30-50%) in this 
conformation at equilibrium, irrespective of assay type. 
The low affinity conformation is likely to be energetically 
less stable than the D-state however, as a relatively small 
increase in the agonist concentration (2nM to lOnM) was 
able to return binding to approximately control values. As 
mentioned earlier, Lippiello et al. (1987) reported that 
only approximately 40% of the receptor population are 
initially in the correct conformation to bind [3H]nicotine 
with high affinity. Adding these elements together, it is 
possible that mecamylamine is able to stabilise the I-state 
of the receptor. This is probably the equivalent of the 
"low affinity state" Lippiello and co-workers. This theory 
has the advantage of providing an explanation of the 
kinetic data. Thus, at 2nM [3H] nicotine, only that 
proportion of the receptor population already in the 
correct conformation to bind the agonist with high affinity
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does so; the amount of radioligand bound is reduced in 
comparison to controls, though the elimination of extensive 
conformational rearrangements reduces the of those
receptors which are labelled. At lOnM [3H]nicotine, 
mecamylamine causes a slight increase in the t^  as it 
attempts to stabilise the less favourable I-state; 
[3H]nicotine binding approximates to that of controls. As 
with chlorisondamine, the site of this interaction is 
unclear, though from oocyte expression studies (Bertrand et 
al., 1990) there is a clear lack of voltage dependence, 
ruling out the channel blocker site. (This fits with the 
previously expressed opinion, that binding at this site 
does not induce a significant conformational change.) 
Mecamylamine was found to rely on agonist activation; 
unsurprising if the antagonist stabilises a conformation 
intermediate between the R- and D-state. Notably, the 
action of mecamylamine bears some resemblance to that of 
progesterone at a4S2 nAChR expressed in Xenoous oocytes 
(Valera et al., 1992), which was also found to be voltage- 
independent, but with some relationship to agonist 
concentration. Single channel recording techniques may 
prove a useful tool in the elucidation of mecamylamine' s 
action, as a stabilisation of the I-state might be expected 
to be reflected in changes in relative contribution of the 
fast and slow phases of receptor desensitisation.
The M10 cell line provides an excellent tool in the 
further exploration of the action of these and other 
antagonists at a4£2 nAChR. The ability to probe both
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antagonists at a4£2 nAChR. The ability to probe both 
functional and desensitised states experimentally, and the 
homogeneity of the system are of great benefit in 
mechanistic analyses. For example, though not performed in 
this study, agonist dose-response curves in the presence of 
fixed concentrations of antagonists might be constructed. 
These would provide information about the mode of 
antagonism; competitive inhibitors would increase the 
concentration of agonist required to achieve full 
activation, NCIs reduce peak response. The influx assay may 
prove unsuitable for this style of experiment however, due 
to the seemingly inherent variability in the response (see 
section 3.3.3) . The use of other radioligands, such as [3H]- 
MK-801, in binding assays would also provide data about the 
sites of interaction of various antagonists with nAChR. 
Competition studies, for example, could be used, though one 
would have to be aware of the possibility of allosteric 
modulation.
5.3 Summary
The nAChR is a dynamic protein whose function, that 
of cation transport across the plasma membrane, is based 
upon allosteric modulation by a wide variety of 
"effectors". These effectors bind at one or more of three 
categories of sites and, depending upon their structure, 
either activate or inactivate the receptor. In most cases 
this binding is accompanied by a spatial rearrangement in 
the peptide chains of the protein which acts as the
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action is essentially an "all-or-none" phenomenon, though 
variation in effector structure around the minimum required 
for function can modulate elements of the ligand/receptor 
interaction. In vivo the number of effectors is limited, 
and this modulation is achieved by varying receptor 
structure, leading to a multiplicity of nAChR subtypes. 
This study has been concerned with the action of two groups 
of effectors - agonists and non-competitive antagonists - 
on one of these receptor subtypes, the a4£2 nAChR.
Agonist action appears to be well defined and most 
rigidly dependent upon effector structure. There are two 
agonist binding sites, spanning the interface of an a. and 
non-a subunit, which contain two important subsites (the 
region around the disulphide, and the negative subsite 
respectively) . The interaction of the agonist and receptor 
leads to a contraction of the site, which, when transmitted 
to the rest of the protein, gives rise to a transient 
channel opening. Continued conformational change leads to 
an enclosure of the agonist, and a concomitant closure of 
the ion channel; the receptor is "desensitised". The four 
agonists used in this study show only minor variations in 
affinity and kinetics.
The mode of action of an antagonist depends upon 
with which region of the nAChR it interacts. Inactivation 
mechanisms may be purely steric, allosteric or a 
combination of the two. However, the presence of multiple 
sites leads to concentration dependent occupation, and 
consequently multiple modes of antagonism by a single
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inhibitor. MK-801 is primarily a channel blocker, DHSE a 
competitive antagonist. Chlorisondamine and mecamylamine 
are both non-channel blocking NCIs, but have dissimilar 
properties; this may be due to different sites of 
interaction.
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Sequence 5.1 Comparative alignments of (A) rat S2/S4
(from Figl et a!., 1992), and (B) chick &2/B4 (Couturier et 
al., 1990b).
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TABLE 1. Comparison ofE C S0 values for AnTx, (-)-nicotine, andACh in different neuronal nAChR preparations
nAChR preparation
EQo (M)
(+)-AnTx (-)-Nicotine ACh
Presynaptic nAChR 1.4 ±  0.4 X  10-7 (3) 4.9 ±0.9 X  10-7 (4) ND
a4fi2 nAChR 4.8 ±  1.8 X  10-* (4) 2.7 ±  0.7 X  10~6 (5) 9.0 ±  4.0 X  10“ 7 (4)
alnAChR 5.8 ±0.9 X  10-7 (5) 2.4 ±0.7 X  10-5 (4) 1.3 ±0.1 X  lO-'4 (5)
Hippocampal neurones 3.9 ±0.6 X  10~6 (6) 2.7 ±  0.5 X  10"5 (5) 1.3 ±0.2 X  lO"4 (7)
Data are mean ±  SE values (no. of preparations). ND, not determined.
tine gives an EC50 o f 2.7 nM , whereas AnTx is ~ 5 0  times 
more potent. Again AnTx produced a steeper dose-re- 
sponse curve than nicotine, and the dose-response curves 
for both drugs are sharper than those obtained from synap- 
tosomes; this may reflect the longer agonist exposure time 
in the ion flux assay.
Dual-electrode voltage-clamp recordings from Xenopus 
oocytes expressing the a l  receptor resulted in characteristi­
cally fast currents that exhibited rapid desensitisation (Cou­
turier et al., 1990). Three-second applications of several 
concentrations of agonist generated the dose-response 
curves depicted in Fig. lc. At this nAChR subtype, nicotine 
is a weaker agonist. Its EC50 value of 24 \iM  is in good agree­
ment with the previously published value of 10 nM  (Ber­
trand et al., 1992). AnTx is 40 times more potent than nico­
tine (Table 1). Again the curve for AnTx is steeper («H = 2.6) 
than that for nicotine (nH = 1.4).
A physiological correlate of the a 7 nAChR may occur in 
hippocampal neurones (Alkondon et al., 1992). These neu­
rones express at least three different nAChRs, based on the 
kinetic properties of agonist-evoked whole-cell currents and 
their relative sensitivities to agonists and antagonists (Al­
kondon and Albuquerque, 1993). Two types of currents, 
referred to as IA and IB, could be blocked by a-Bgt. The 
type of current most frequently recorded (occurring in 
>80% of the hippocampal neurones tested) was I A, which 
exhibited a fast decay, reminiscent o f al expressed in oo­
cytes. In the present study, AnTx, nicotine, and ACh were 
compared on type IA nAChRs (Fig. 2). AnTx was the most 
potent and efficacious agonist, being seven times more po­
tent than nicotine and 30 times more potent than ACh (Ta­
ble 1). EC50 values for nicotine and ACh at the hippocampal 
type IA nAChR were in good agreement with values ob­
tained for the reconstituted al nAChR, but AnTx appeared 
to be more potent at the latter (Table 1).
I A
ACh
(30 /aM)
AnTX 
(1 M M)
(-)Nic --- 1 (
(10 juM)
 1100 pA
BOO1 ms
FIG. 2. Sample recordings of whole-cell currents (type IA) elicited 
in a cultured hippocampal neuron by AnTx (1 fiM), nicotine (Nic; 
10 fiM), and ACh (30 fiM). The holding potential was -50 mV, and 
the cell was cultured for 30 days.
In all four nAChR preparations studied here, represent­
ing at least two distinct nAChR subtypes, namely* a4(32 and 
al, AnTx is a potent agonist, with submicromolair EC50 val­
ues in most cases (Table 1). EC50 values for nicoTine range 
from 0.5 \lM  in hippocampal synaptosomes to ~ 2 5  [lM at 
the a-Bgt-sensitive nAChR; in each preparation, nicotine 
has at least a threefold lower potency than AnTx. The endog­
enous agonist ACh had a potency similar to or less than that 
of (-)-nicotine and was clearly less potent than AnTx in 
each case (Table 1).
In ligand binding assays for [3H] nicotine or l25I-a-Bgt 
binding sites the rank order of potency of AnTx* (-^ n ico­
tine, and ACh is similar to that in Table 1 (MacAllan et al., 
1988; Wonnacott et al., 1991; Grady etal., 1992).. Compari­
son of K{ and EC50 values shows the former to be generally 
one or two orders of magnitude higher. This is considered to 
reflect the propensity of agonists to convert the receptor into 
a high-affinity desensitised configuration and precludes the 
quantitative comparison of equilibrium binding data with 
functional estimates of agonist potency (Grady et al., 1992). 
Binding studies suggest that cytisine is a more potent ligand 
than (-)-nicotine (Whiting etal., 1991; Grady et al., 1992). 
However, the agonist potency of cytisine is very dependent 
on the subunit composition of the nAChR (Luetje and Pat­
rick, 1991), and EC50 values for cytisine at different nAChR 
subtypes are similar to those for (-)-nicotine (Bertrand et 
al., 1992; Grady et al., 1992). In the four preparations de­
scribed here, cytisine had potencies similar to or less than 
that o f (-)-nicotine (data not shown) and was clearly less 
potent than AnTx. When its potency at the muscle nAChR 
(Swanson et al., 1986) is also considered, AnTx is the most 
potent nicotinic agonist thus far identified.
Because of the rigid structure of the azabicyclononene 
ring of AnTx, its high (probably exclusive) stereoselectivity 
for the (+)-enantiomer, and the available synthetic chemis­
try, AnTx is an attractive lead compound for structure- 
activity studies (Swanson et al., 1991; Wonnacott et al., 
1991, 1992). Furthermore, the ability o f AnTx, a secondary 
amine, to enter the brain from the systemic circulation (Sto- 
lerman et al., 1992) and its potential for chemical modifica­
tion to create radiolabelled and affinity ligands (Huby et al., 
1991; Wonnacott et al., 1992) make AnTx an excellent 
probe for the neuronal nAChR.
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BOOK REVIEWS
Fidia Research Foundation Neuroscience Award Lectures, 
Vol. 4,1988-1989. ISBN 0-88167-671-3. Price: U.S. $109.50. 
Raven Press Ltd, New York, 1990.
This is the fourth volume in the rather good series of invited 
lectures organized by the Fidia Research Foundation, and 
presented at Georgetown University, Washington, during 
1988 and 1989. This volume comprises contributions from 
Jean-Pierre Changeux, Rudolfo Llinas, Dale Purves and 
Floyd Bloom, each preceded by a short biographical sketch 
of the eminent neuroscientist in whose honour the lecture 
was given. This feature, together with the historical context 
of their topic offered by some of the contributors, pro­
vides an interesting perspective for the modem student of 
neuroscience.
This volume commences with an additional contribution 
by Edmund Pellegrino on Medical Ethics, a topic oddly out 
of place here. It is not an essay on the ethics of brain grafts, 
or genetic counselling in relation to inherited neurological 
diseases, but rather debates the relevance of Hippocratic 
ethics to modem medicine. There is little or no mention of 
Neuroscience and, contrary to the title of the volume, this is 
not offered as a Neuroscience Award Lecture. One wonders, 
therefore, what this essay is doing here.
The second contribution, which rather dominates the 
book, is an extensive yet highly readable review of the nico­
tinic acetylcholine receptor: “An alosteric ligand-gated ion 
channel”, by Jean-Pierre Changeux. The author’s attempt to 
integrate a historical narrative with a discussion of current 
models of structure and function works well. Thus we are 
introduced to Claude Bernard’s studies with curare, and 
Langley’s concept of a “receptive substance” . This idea is 
developed to give a lucid account of the prototypical allo- 
steric transmembrane protein.
The ‘intrinsic electroresponsive properties’ of nerve cells 
form the basis of Rudolfo Lianas’ lecture. The author pro­
vides evidence for different electrical properties between cell 
types, adding weight to the view that even if all other things 
were identical (synaptic connectivity and transmitter output) 
a neuron of a given type could not be replaced by another. 
Ending with a model integrating these properties, the author 
envisages the brain operating “not as a slumbering machine 
awoken by . . .  sensory information” , but as a “continuously 
humming” entity.
Is neuronal circuitry more or less structurally fixed or 
can it be altered during learning for example? Dale Purves, 
though accepting such changes are unlikely in the short term, 
believes that slowly developing, long term behavioural 
changes may, quite plausibly, be due to ongoing alterations 
in the connections between pre- and post-synaptic processes. 
Presenting evidence from both the peripheral and central 
nervous systems, the author suggests such changes may be 
commonplace, particularly in systems where multiple inner­
vation of target cells is seen.
Floyd Bloom attempts to review the role of peptides as
regulators of cell function in the brain. Acknowledging that 
a comprehensive survey is impossible when the number of 
peptides seems to be increasing almost exponentially, the 
author chooses to look at the detection, localization and 
characterization of a few specific examples. These include his 
own work on an immunoglobulin-like brain specific adhesion 
molecule (1B236). Also addressed is the interplay between 
peptides and classical neurotransmitters (such as soma­
tostatin and ACh).
In conclusion, although the character of the contributions 
is rather varied (ranging from Changeux’s comprehensive 
review to the briefer, more personal accounts of the other 
authors), this is an attractive collection of essays that many 
neuroscientists will find enjoyable and instructive to read.
M. W. Stephens and S. Wonnacott
Drs Stephens and Wonnacott are at the Department o f
Biochemistry, University o f Bath, Bath, Avon, U.K.
Neurology and Neurobiology, Vol. 57, Catecholamine Genes. 
Edited byT. H. Joh. ISBN 0-471-56769-8. Price: U.S. $79.95. 
Wiley-Liss, 1990.
The rapid expansion of molecular neurobiology in the world 
of neuroscience fully justify the edition of the present volume 
of the series Neurology and Neurobiology. Many genes related 
to neuronal activities have been characterized and structure- 
function relationships of these genes are now extensively 
studied. The genes of the catecholamines-related enzymes are 
probably among the more fully characterized. The present 
volume, Catecholamines Genes, was then devoted to the 
summary of recent progress in this field.
We can however regret that the J. Mallet’s group, one of 
the major contributors to this field and well recognized since 
their works are cited in 7 on 10 chapters of this book, lacks 
as a contributor of this up-to-date volume.
This volume focuses mostly, in 5 on 10 chapters, on the 
rate limiting enzyme in catecholamine biosynthesis, tyrosine 
hydroxylase (TH). Two chapters review recent findings on 
multiple messenger RNA (mRNA) of human TH. They char­
acterized the human TH gene and the alternative RNA 
splicing producing four types of TH mRNA from the same 
primary transcripts. Tissue-specific expression of these four 
types of human TH, transcriptional regulation in the pro­
moter region, and finally generation of stable mammalian 
cell lines independently expressing individual TH isoenzymes 
are developed in these chapters. The problem of trans­
criptional and post-transcriptional regulation of TH mRNA 
is more deeply examined in two additional chapters. The last 
chapter reviews the data on the evolution of TH. The authors 
state that TH gene belongs to a gene family constituted by 
the three aromatic acid hydroxylase genes and propose a 
model based on current genomic structures for the evolution 
of the ancestral hydroxylase gene.
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Three chapters focus on the phenyletanolamine TV-methyl- 
transferase (PNMT), an enzyme serving as a specific cell 
marker for the adrenergic phenotype. The isolation, identi­
fication and nucleotide sequence of a cDNA and genomic 
DNA clone encoding bovine PN M T; the study of the PNMT 
promoter including the characterization of a glucocorticoid 
response element; and the different aspects of transcriptional 
regulation of this PNMT mRNA are developed in these 
chapters.
Unfortunately, making the history incomplete, no chap­
ters were devoted to the two other enzymes in catecholamine 
biosynthesis: aromatic L-amino acid decarboxylase (AADC) 
and dopamine beta-hydroxylase (DBH) despite both being 
recently cloned. However, in its introductory chapter Tong 
Joh, the editor, briefly summarizes recent data on AADC 
and DBH.
Finally and interestingly, the last chapter of this issue 
concerns the cloning and expression of human monoamine 
oxidase A and B, two catecholamines metabolizing enzymes. 
These recently reported results open the way for a better 
understanding of these enzymes and a better use of their 
inhibitors in therapeutics.
All chapters of this book mix up-to-date reviews and pre­
cise and concise description of results and used methods and 
they demonstrate how large is the part taken by molecular 
neurobiology in the advance in understanding of cate­
cholamine enzyme. It will be very useful for all phar­
macologists and neuroscientists, particularly those involved 
in neurotransmitter research and also for neurologists 
involved in neurodegenerative diseases.
We are waiting now for an equally useful issue of the 
Neurology and Neurobiology series on catecholamine recep­
tor genes.
Professor Je a n -Jac q u e s V a n d e r h a e g h e n  
Professor Vanderhaeghen is at the Neuropathology-Neuro- 
peptides Laboratory, Universite Libre de Bruxelles, Campus 
Erasme Anderlecht, Batiment C, CP 601,808 route de Lennik, 
1070 Brussels, Belgium.
Trophic Factors and the Nervous System. Fidia Research 
Foundation Symposium Series. Vol. 3. Edited by L. A. Hor- 
rocks, N. H. Neff, A. J. Yates and M. Hadjiconstantinou. 
ISBN 0-88167-671-3. Price: US$109.50. Raven Press, New 
York, 1990.
Factors which promote growth, development and differ­
entiation of neurons are currently the topic of numerous 
experimental studies and therefore it seems justified to collect 
reviews concerning these factors. As is often the case the 
nerve growth factor attracts most of the attention and in this 
collection of papers from a Symposium held at the Ohio State 
University in 1989 9 out of 24 contributions specifically deal 
with this important protein. However, many other sub­
stances influencing neuronal differentiation are described 
ranging from classical neurotransmitters over gangliosides 
to different peptides. A couple of papers are devoted to a 
detailed discussion of the role of calcium in the control of 
neuronal growth. Particularly the chapter by Stanley Kater 
and coworkers gives an excellent overview of the importance 
of the level of the intracellular free calcium concentration for 
the behavior of the neuronal growth cone. With regard to 
the understanding of the molecular events at the gene level 
which regulate neuronal differentiation, the introductory 
chapter by Erminio Costa is very useful. Also the chapter by 
Silvio Varon and coworkers on in vivo effects of nerve growth 
factor on degenerating cholinergic neurons is interesting.
Altogether this collection of review papers gives a very • 
useful up-to-date picture of this extremely active field. The 
subject index gives easy access to the book and as is cus­
tomary for these types of books there is a list of contributors. 
The book will be useful for those interested in neuro­
degenerative diseases with special emphasis on regeneration 
processes.
A r n e  Sc h o u s b o e
Professor Schousboe is at the PharmaBiotec Research Center, 
Department o f Biological Sciences, Royal Danish School o f 
Pharmacy, 2100 Copenhagen 0 , Denmark.
